Publication Page  
  L-MARC Home Page  ::  
   
Cholesterol & Lipid Publications

 

JOURNALS

Bays HE, Leiter LA, Colhoun HM, Thompson D, Bessac L, Pordy R, Toth PP. Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials. J Am Heart Assoc. 2017 Aug 8;6(8)

Bays HE, Patel MD, Mavros P, Ramey DR, Tomassini JE, Tershakovec AM, Baxter CA. Real-world data to assess changes in low-density lipoprotein cholesterol and predicted cardiovascular risk after ezetimibe discontinuation post reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial. J Clin Lipidol. 2017 May 8. pii: S1933-2874(17)30289-1

Bays HE, Sartipy P, Xu J, Sjöström CD, Underberg JA. Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels. J Clin Lipidol. 2017 Mar - Apr;11(2):450-458

Mosca L, Ballantyne CM, Bays HE, Guyton JR, Philip S, Doyle RT Jr, Juliano RA. Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials). Am J Cardiol. 2017 Feb 1;119(3):397-403. doi: 10.1016/j.amjcard.2016.10.027. PubMed PMID: 27939227.

Kastelein JJ, Kereiakes DJ, Cannon CP, Bays HE, Minini P, Lee LV, Maroni J, Farnier M. Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia. Coron Artery Dis. 2016 Oct 12. [Epub ahead of print] PubMed PMID: 27740972.

Jones PH, Bays HE, Chaudhari U, Pordy R, Lorenzato C, Miller K, Robinson JG. Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials. Am J Cardiol. 2016 Dec 15;118(12):1805-1811. doi: 10.1016/j.amjcard.2016.08.072. PubMed PMID: 27729106.

Stein E, Bays H, Koren M, Bakker-Arkema R, Bisgaier C. Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients. J Clin Lipidol. 2016 Sep-Oct;10(5):1212-22. doi: 10.1016/j.jacl.2016.08.002. PubMed PMID: 27678439.

Ballantyne CM, Bays HE, Philip S, Doyle RT Jr, Braeckman RA, Stirtan WG, Soni PN, Juliano RA. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. Atherosclerosis. 2016 Oct;253:81-87. doi: 10.1016/j.atherosclerosis.2016.08.005. PubMed PMID: 27596132.

Bays HE, Ballantyne CM, Doyle RT Jr, Juliano RA, Philip S. Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. Prostaglandins Other Lipid Mediat. 2016 Sep;125:57-64. doi: 10.1016/j.prostaglandins.2016.07.007. PubMed PMID: 27418543.

Ballantyne CM, Bays HE, Braeckman RA, Philip S, Stirtan WG, Doyle RT Jr, Soni PN, Juliano RA. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. J Clin Lipidol. 2016 May-Jun;10(3):635-645.e1. doi: 10.1016/j.jacl.2016.02.008. PubMed PMID: 27206952.

Kastelein JJ, Hallén J, Vige R, Fraser DA, Zhou R, Hustvedt SO, Orloff DG, Bays HE. Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia. Cardiology. 2016;135(1):3-12. doi: 10.1159/000445047. PubMed PMID: 27160246.

Bays HE, Jones PH, Orringer CE, Brown WV, Jacobson TA. National Lipid Association Annual Summary of Clinical Lipidology 2016. J Clin Lipidol. 2016 Jan-Feb;10(1 Suppl):S1-S43.

Abstract: The National Lipid Association (NLA) Annual Summary of Clinical Lipidology is a yearly updated summary of principles important to the patient-centered evaluation, management, and care of patients with dyslipidemia. This summary is intended to be a "living document," with future annual updates based on emerging science, clinical considerations, and new NLA Position, Consensus, and Scientific Statements, thus providing an ongoing resource that applies the latest in medical science towards the clinical management of patients with dyslipidemia. Topics include the NLA Recommendations for Patient-Centered Management of Dyslipidemia, genetics, Familial Hypercholesterolemia, secondary causes of dyslipidemia, biomarkers and advanced lipid testing, nutrition, physical activity, obesity, adiposopathy, metabolic syndrome, diabetes mellitus, lipid pharmacotherapy, lipid-altering drug interactions, lipoprotein apheresis, dyslipidemia management and treatment based upon age (children, adolescents, and older individuals), dyslipidemia considerations based upon race, ethnicity and gender, dyslipidemia and human immune virus infection, dyslipidemia and immune disorders, adherence strategies and collaborative care, and lipid-altering drugs in development. Hyperlinks direct the reader to sentinel online tables, charts, and figures relevant to lipidology, access to online atherosclerotic cardiovascular disease risk calculators, worldwide lipid guidelines, recommendations, and position/scientific statements, as well as links to online audio files, websites, slide shows, applications, continuing medical education opportunities, and patient information. (CLICK HERE FOR A FREE DOWNLOAD OF THIS ARTICLE)

Bays HE, Jones PH, Jacobson TA, Cohen DE, Orringer CE, Kothari S, Azagury DE, Morton J, Nguyen NT, Westman EC, Horn DB, Scinta W, Primack C. Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: FULL REPORT. J Clin Lipidol. 2016 Jan-Feb;10(1):33-57.

Abstract: Bariatric procedures often improve lipid levels in patients with obesity. This 2 part scientific statement examines the potential lipid benefits of bariatric procedures and represents the contributions from authors representing the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and the Obesity Medicine Association. The foundation for this scientific statement was based on published data through June 2015. Part 1 of this 2 part scientific statement provides an overview of: (1) adipose tissue, cholesterol metabolism, and lipids; (2) bariatric procedures, cholesterol metabolism, and lipids; (3) endocrine factors relevant to lipid influx, synthesis, metabolism, and efflux; (4) immune factors relevant to lipid influx, synthesis, metabolism, and efflux; (5) bariatric procedures, bile acid metabolism, and lipids; and (6) bariatric procedures, intestinal microbiota, and lipids, with specific emphasis on how the alterations in the microbiome by bariatric procedures influence obesity, bile acids, and inflammation, which in turn, may all affect lipid levels. Included in part 2 of this comprehensive scientific statement will be a review of (1) the importance of nutrients (fats, carbohydrates, and proteins) and their absorption on lipid levels; (2) the effects of bariatric procedures on gut hormones and lipid levels; (3) the effects of bariatric procedures on nonlipid cardiovascular disease (CVD) risk factors; (4) the effects of bariatric procedures on lipid levels; (5) effects of bariatric procedures on CVD; and finally, (6) the potential lipid effects of vitamin, mineral, and trace element deficiencies that may occur after bariatric procedures. This document represents the full report of part 1. (CLICK HERE FOR A FREE DOWNLOAD OF THIS ARTICLE

Bays HE, Jones PH, Jacobson TA, Cohen DE, Orringer CE, Kothari S, Azagury DE, Morton J, Nguyen NT, Westman EC, Horn DB, Scinta W, Primack C. Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: EXECUTIVE SUMMARY. J Clin Lipidol. 2016 Jan-Feb;10(1):15-32.

Bays H, Kothari SN, Azagury DE, Morton JM, Nguyen NT, Jones PH, Jacobson TA, Cohen DE, Orringer C, Westman EC, Horn DB, Scinta W, Primack C. Lipids and bariatric procedures Part 2 of 2: scientific statement from the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and Obesity Medicine Association (OMA). Surg Obes Relat Dis. 2016 Jan 12. pii: S1550-7289(16)00011-3. doi: 10.1016/j.soard.2016.01.007. [Epub ahead of print] PubMed PMID: 27050404.

Abstract: Bariatric procedures generally improve dyslipidemia, sometimes substantially so.  Bariatric procedures also improve other major cardiovascular risk factors.  This 2-part Scientific Statement examines the lipid effects of bariatric procedures and reflects contributions from authors representing the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and the Obesity Medicine Association (OMA).  Part1 was published in the Journal of Clinical Lipidology, and reviewed the impact of bariatric procedures upon adipose tissue endocrine and immune factors, adipose tissue lipid metabolism, as well as the lipid effects of bariatric procedures relative to bile acids and intestinal microbiota.  This Part 2 reviews: (1) the importance of nutrients (fats, carbohydrates, and proteins) and their absorption on lipid levels;  (2) the effects of bariatric procedures on gut hormones and lipid levels; (3)the effects of bariatric procedures on nonlipid cardiovascular disease (CVD) risk factors; (4)the effects of bariatric procedures on lipid levels; (5)effects of bariatric procedures on CVD; and finally, (6)the potential lipid effects of vitamin, mineral, and trace element deficiencies, that may occur after bariatric procedures.  Surg Obes Relat Dis 2016 American Society for Metabolic and Bariatric Surgery.

Bays HE. A lipidologist perspective of global lipid guidelines and recommendations, part 1: Lipid treatment targets and risk assessment. J Clin Lipidol. 2016 Mar-Apr;10(2):228-39.

Bays HE. A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals. J Clin Lipidol. 2016 Mar-Apr;10(2):240-64.

Bays HE, Hallén J, Vige R, Fraser D, Zhou R, Hustvedt SO, Orloff DG, Kastelein JJ. Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial. J Clin Lipidol. 2016 Jan-Feb;10(1):181-191.

Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, La Forge R, Daniels SR, Wilson DP, Morris PB, Wild RA, Grundy SM, Daviglus M, Ferdinand KC, Vijayaraghavan K, Deedwania PC, Aberg JA, Liao KP, McKenney JM, Ross JL, Braun LT, Ito MK, Bays HE, Brown WV; NLA Expert Panel. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. J Clin Lipidol. 2015 Nov-Dec;9(6 Suppl):S1-S122.e1.

Orringer CE, Bays HE, Brown WV. Clinical lipidology: A subspecialty whose time has come. J Clin Lipidol. 2015 Sep-Oct;9(5):634-9.

Brown WV, Bays HE, La Forge R, Sikand G. JCL Roundtable: Gender differences in risk reduction with lifestyle changes. J Clin Lipidol. 2015 Jul-Aug;9(4):486-95.

Ballantyne CM, Braeckman RA, Bays HE, Kastelein JJ, Otvos JD, Stirtan WG, Doyle RT Jr, Soni PN, Juliano RA. Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study). J Clin Lipidol. 2015 May-Jun;9(3):377-83. doi: 10.1016/j.jacl.2014.11.009. Epub 2014 Nov 29. PubMed PMID: 26073397.

McKenney J, Bays H, Gleim G, Mitchel Y, Kuznetsova O, Sapre A, Sirah W, Maccubbin D. Safety and tolerability of extended-release niacin-laropiprant: Pooled analyses for 11,310 patients in 12 controlled clinical trials. J Clin Lipidol. 2015 May-Jun;9(3):313-25. .

Bays H, Gaudet D, Weiss R, Ruiz JL, Watts GF, Gouni-Berthold I, Robinson J, Zhao J, Hanotin C, Donahue S. Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. J Clin Endocrinol Metab. 2015 Aug;100(8):3140-8.

Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, Wilson DP, Brown WV. National lipid association recommendations for patient-centered management of dyslipidemia: part 1-full report. J Clin Lipidol. 2015 Mar-Apr;9(2):129-69.

Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Doyle RT Jr, Philip S, Soni PN, Juliano RA. Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome. Metab Syndr Relat Disord. 2015 Aug;13(6):239-47

Bays HE, Jones PH, Brown WV, Jacobson TA. National lipid association annual summary of clinical lipidology 2015. J Clin Lipidol. 2014 Nov-Dec;8(6 Suppl):S1-S36.

Abstract: The National Lipid Association (NLA) Annual Summary of Clinical Lipidology 2015 is a summary of principles important to the patient-centered evaluation, management, and care of patients with dyslipidemia. This summary is intended to be a "living document," with future annual updates based on emerging science, clinical considerations, and new NLA Position and Consensus Statements. The goal is to provide clinicians an ongoing resource that translates the latest advances in medical science toward the evaluation and treatment of patients with dyslipidemia. The 2015 NLA Annual Summary of Clinical Lipidology was founded on the principles of evidence-based medicine and is generally consistent with established national and international lipid guidelines. Topics include a general discussion of the 2014 NLA Recommendations for Patient-Centered Management of Dyslipidemia, genetics, secondary causes of dyslipidemia, biomarkers and "advanced lipid testing," medical nutrition, physical activity, obesity, pharmacotherapy, statin safety, lipid-altering drug interactions, lipoprotein apheresis, dyslipidemia in children and adolescence, dyslipidemia in older individuals, race/ethnicity, and women, health information technology and electronic medical records, as well as investigational lipid-altering drugs in development.

Ballantyne CM, Neutel J, Cropp A, Duggan W, Wang EQ, Plowchalk D, Sweeney K, Kaila N, Vincent J, Bays H. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol. 2015 May 1;115(9):1212-21.

Bays HE, Brinton EA, Triscari J, Chen E, Maccubbin D, MacLean AA, Gibson KL, Ruck RA, Johnson-Levonas AO, O'Neill EA, Mitchel YB. Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control. Vasc Health Risk Manag. 2015 Feb 24;11:165-72.

Bays HE, Chen E, Tomassini JE, McPeters G, Polis AB, Triscari J. Fixed-dose combination ezetimibe+atorvastatin lowers LDL-C equivalent to co-administered components in randomized trials: use of a dose-response model. Fundam Clin Pharmacol. 2015 Apr;29(2):209-18.

Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, Kim JB, Scott R, Wasserman SM, Bays H; MENDEL-2 Investigators. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014 Jun 17;63(23):2531-40. doi: 10.1016/j.jacc.2014.03.018. Epub 2014 Mar 29

Moriarty PM, Roth EM, Karns A, Ye P, Zhao SP, Liao Y, Capuzzi DM, Bays HE, Zhang F, Liu S, Reichman AJ, Brusco OA, Lu G, Lerman S, Duan Z, Guo S, Liu PL, Zhao J, Zhang Y, Li S. Effects of Xuezhikang in patients with dyslipidemia: A multicenter, randomized, placebo-controlled study. J Clin Lipidol. 2014 Nov-Dec;8(6):568-75.

Robinson JG, Colhoun HM, Bays HE, Jones PH, Du Y, Hanotin C, Donahue S. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies. Clin Cardiol. 2014 Oct;37(10):597-604. doi: 10.1002/clc.22327. Epub 2014 Sep 30. PubMed PMID: 25269777.

Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, Wilson DP, Brown WV. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. J Clin Lipidol. 2014 Sep-Oct;8(5):473-88. doi: 10.1016/j.jacl.2014.07.007. Epub 2014 Jul 15. PubMed PMID: 25234560.

Guyton JR, Bays HE, Grundy SM, Jacobson TA. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol. 2014 May-Jun;8(3 Suppl):S72-81. doi: 10.1016/j.jacl.2014.03.002. PubMed PMID: 24793444.

Bays H, Cohen DE, Chalasani N, Harrison SA. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol. 2014 May-Jun;8(3 Suppl):S47-57. doi: 10.1016/j.jacl.2014.02.011. PubMed PMID: 24793441.

Bays HE. Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus. Int J Gen Med. 2014 Jul 5;7:355-64. doi: 10.2147/IJGM.S65148. eCollection 2014. Review. PubMed PMID: 25045281; PubMed Central PMCID: PMC4094576.

Brown WV, Bays H, Bray GA. JCL Roundtable: Clinical management of individuals with obesity. J Clin Lipidol. 2014 May - June;8(3):237-248. doi: 10.1016/j.jacl.2014.02.005. Epub 2014 Feb 15. Review. PubMed PMID: 24793344.

Schwab P, Louder A, Li Y, Mallick R, Bays H. Cholesterol treatment patterns and cardiovascular clinical outcomes associated with colesevelam HCl and ezetimibe. Drugs Aging. 2014 Sep;31(9):683-94. doi: 10.1007/s40266-014-0200-6. PubMed PMID: 25091271.

Swindle JP, Ye X, Mallick R, Song R, Horstman T, Bays HE. Colesevelam, Ezetimibe, and Patients With Type 2 Diabetes Mellitus: Characteristics and Clinical Outcomes From a Health Care Database. Ann Pharmacother. 2014 Apr 16. [Epub ahead of print] PubMed PMID: 24740470.

Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, Blom D, Eriksson M, Dent R, Wasserman SM, Huang F, Xue A, Albizem M, Scott R, Stein EA. Reduction in lipoprotein (a) with the PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of over 1300 patients in 4 phase 2 trials. J Am Coll Cardiol. 2014 Jan 27. pii: S0735-1097(14)00281-2. doi: 10.1016/j.jacc.2014.01.006. [Epub ahead of print] PubMed PMID: 24509273

Bays HE, Averna M, Majul C, Muller-Wieland D, De Pellegrin A, Giezek H, Lee R, Lowe RS, Brudi P, Triscari J, Farnier M. Efficacy and Safety of Ezetimibe Added to Atorvastatin Versus Atorvastatin Uptitration or Switching to Rosuvastatin in Patients With Primary Hypercholesterolemia. Am J Cardiol. 2013 112(12):1885-95

Friedewald VE, Ballantyne CM, Bays HE, Jones PH. The Editor's Roundtable: Hypertriglyceridemia. Am J Cardiol. 2013 Oct 15;112(8):1133-1141. doi: 10.1016/j.amjcard.2013.07.033

Bays HE, Toth PP, Kris-Etherton PM, Abate N, Aronne LJ, Brown WV, Gonzalez-Campoy JM, Jones SR, Kumar R, La Forge R, Samuel VT. Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association. J Clin Lipidol. 2013 Jul-Aug;7(4):304-83. doi: 10.1016/j.jacl.2013.04.001. Epub 2013 May 31

Abstract: The term "fat" may refer to lipids as well as the cells and tissue that store lipid (ie, adipocytes and adipose tissue). "Lipid" is derived from "lipos," which refers to animal fat or vegetable oil. Adiposity refers to body fat and is derived from "adipo," referring to fat. Adipocytes and adipose tissue store the greatest amount of body lipids, including triglycerides and free cholesterol. Adipocytes and adipose tissue are active from an endocrine and immune standpoint. Adipocyte hypertrophy and excessive adipose tissue accumulation can promote pathogenic adipocyte and adipose tissue effects (adiposopathy), resulting in abnormal levels of circulating lipids, with dyslipidemia being a major atherosclerotic coronary heart disease risk factor. It is therefore incumbent upon lipidologists to be among the most knowledgeable in the understanding of the relationship between excessive body fat and dyslipidemia. On September 16, 2012, the National Lipid Association held a Consensus Conference with the goal of better defining the effect of adiposity on lipoproteins, how the pathos of excessive body fat (adiposopathy) contributes to dyslipidemia, and how therapies such as appropriate nutrition, increased physical activity, weight-management drugs, and bariatric surgery might be expected to impact dyslipidemia. It is hoped that the information derived from these proceedings will promote a greater appreciation among clinicians of the impact of excess adiposity and its treatment on dyslipidemia and prompt more research on the effects of interventions for improving dyslipidemia and reducing cardiovascular disease risk in overweight and obese patients.

Braeckman RA, Manku MS, Bays HE, Stirtan WG, Soni PN. Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study). Prostaglandins Leukot Essent Fatty Acids 2013 [Epub ahead of print]

Brinton EA, Ballantyne CM, Bays HE, Kastelein JJ, Braeckman RA, Soni PN. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200--500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovasc Diabetol. 2013 Jul 9;12(1):100. [Epub ahead of print]

Ballantyne CM, Davidson MH, Macdougall DE, Bays HE, Dicarlo LA, Rosenberg NL, Margulies J, Newton RS. Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate - Citrate Lyase and Adenosine Monophosphate - Activated Protein Kinase in Subjects with Hypercholesterolemia: The Results of a Double-Blind, Parallel Group, Multicenter, Placebo Controlled Trial. J Am Coll Cardiol. 2013 Jun 12. [Epub ahead of print]

Ye X, Bays H, Swindle JP. Colesevelam HCl or ezetimibe for hypercholesterolemia: differences in patient characteristics from a health care database. Value Health. 16 (3) 2013

Ye X, Bays H, Schwab P. Concomitant statin use with ezetimibe or colesevelam for treatment of hypercholesterolemia. Value Health. 16 (3) 2013.

Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN. Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies. Am J Cardiovasc Drugs. 2013 Jan 17. [Epub ahead of print]

Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN. Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). J Clin Lipidol. 2012 Nov;6(6):565-72.

Ballantyne CM, Bays HE, Braeckman RA, Soni PN. Authors' reply. Am J Cardiol. 2013 Feb 1;111(3):455-6.

Brown WV, Bays HE, Maki KC, Wild RA. Planning a clinical trial. J Clin Lipidol. 2012 Nov;6(6):484-95. Epub 2012 Oct 5.

Bays HE, Evans JL, Maki KC, Evans M, Maquet V, Cooper R, Anderson JW. Chitin-glucan fiber effects on oxidized low-density lipoprotein: a randomized trial. Eur J Clin Nutr. 2012 Epub ahead of print

Bays HE. Long-term (52-78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients. Diabetes Metab Syndr Obes 2012;5:125-34.

Maki KC, Bays HE, Dicklin MR. Treatment options for the management of hypertriglyceridemia: Strategies based on the best available evidence. J Clin lipidol. 2012;6:413-26.

Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study). Am J Cardiol. 2012;110(7):984-92.

Maccubbin DL, Chen F, Anderson JW, Sirah W, McCrary Sisk, Kher U, Olsson AG, Bays HE, Mitchel YB. Effectiveness and Safety of Laropiprant on Niacin-Induced Flushing. Am J Cardiol 2012;110:817-22.

Bays HE, Shah A, Lin J, Sisk CM, Dong Q, Maccubbin D. Consistency of Extended-Release Niacin/Laropiprant Effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 Ratio Across Patient Subgroups. Am J Cardiovasc Drugs 2012;12:197-206.

Bays H, Giezek H, McKenney JM, O'Neil EA, Tershakovec AM. Extended-Release Niacin/Laropiprant Effects on Lipoprotein Subfractions in Patients with Type 2 Diabetes Mellitus. Metab Syndr Relat Disord. 2012. 10:260-266.

Bays HE. Specialty Corner: Investigational Anti-obesity Agents to Treat Adiposopathy and "Sick Fat." Lipid Spin. Pages 22-23. 2011

Brown WV, Bays H, Harris W, Miller M. Using omega-3 fatty acids in the practice of clinical lipidology. J Clin Lipidol. 2011;5(6):424-33.

Maki KC, Bays HE, Dicklin MR, Johnson SL, Shabbout M. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating leels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A (2) mass in men and women with mixed dyslipidemia. J Clin Lipidol. 2011;5(6):483-92.

Bays HE. Colesevelam HCl added to background metformin therapy in patients with type 2 diabetes mellitus: A pooled analysis from three clinical studies. Endocrine Practice. Endocr Pract. 2011;17:933-938.

Bays HE, Schwartz S, Littlejohn T 3rd, Kerzner B, Krauss RM, Karpf DB, Choi YJ, Wang X, Naim S, Roberts BK. MBX-8025, A Novel Peroxisome Proliferator Receptor-deta Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with or without Atorvastatin. J Clin Endocrinol Metab 2011;96:2889-97

Stalenhoef AF, Davidson MH, Robinson JG, Burgess T, Duttlinger-Maddux R, Kallend D, Goldberg AC, Bays H. Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk. Diabetes Obes Metab 2011 Epub ahead of print.

Bays HE, Ballantyne CM, Kastelein JJ, Issacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic Acid Ethyl Ester (AMR 101) Therapy in Patients With Very High Triglyceride Levels (from the Muticenter, plAcebo-controlled, Randomized, double-bliNd, 12-week study with an open-label Extension [MARINE] Trial). Am J Cardiol 2011 108;5:682-690

Bays HE. Adiposopathy: Is "Sick Fat" a Cardiovascular Disease? Journal of the American College of Cardiology. 2011;57:2461-2473. (CLICK HERE FOR ONLINE MEDSCAPE REPRINT OF THIS ARTICLE)

Bays HE, Davidson MH, Massaad R, Flaim D, Lowe RS, Tershakovec AM, Jones-Burton C. Safety and Efficacy of Ezetimibe Added on to Rosuvastatin 5 or 10 mg Versus Up-Titration of Rosuvastatin in Patients With Hypercholesterolemia (the ACTE Study) Am J Cardiol 2011;108:523-530

Stein EA, Bays H, O'Brien D, Pedicano J, Piper E, Spezzi A. Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia. Circulation. 2011 10;123:1974-85.

Bays H, Shah A, Dong Q, McCrary Sisk C, Maccubbin D. Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. Int J Clin Pract. 2011 65(4):436-45.

Brown WV, Bays H, Davidson M, Goldberg A. Drugs in development for management of lipoprotein disorders. J Clin Lipidol. 2011 5(2):66-75.

MacLean A, McKenney JM, Scott R, Brinton E, Bays HE, Mitchel YB, Paolini JF, Giezek H, Vandormael K, Ruck RA, Gibson K, Sisk CM, Maccubbin DL. Efficacy and safety of extended-release niacin/laropiprant in patients with type 2 diabetes mellitus. British Journal of Cardiology Volume 8 February 2011 (Published ahead of print)

Bays H, Conard S, Leiter LA, Bird S, Jensen E, Hanson ME, Shah A, Tershakovec AM. Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading? Lipids Health Dis. 2010 30;9:136

Bays HE, Shah A, Macdonell G, Taggart WV, Gumbiner B. Effects of Coadministered Ezetimibe Plus Fenofibrate in Mixed Dyslipidemic Patients with Metabolic Syndrome. Metab Syndr Relat Disord. 2010 Nov 30. [Epub ahead of print]

Bays HE, Shah A, Lin J, McCrary Sisk C, Paolini JF, Maccubbin D. Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. J Clin Lipidol. 2010 November - December;4(6):515-521. Epub 2010 Oct 28.

Bays HE, Gonzalez-Campoy JM, Schorr AB. What men should know about metabolic syndrome, adiposopathy, and "sick fat." Int J Clin Pract. 2010;64:1735-1739.

Leiter LA, Bays H, Conard S, Lin J, Hanson ME, Shah A, Tershakovec AM. Attainment of Canadian and European guidelines' lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin. Int J Clin Pract. 2010 Oct 14.

Bays HE, Maki KC, Schmitz K. Colesevelam HCl Powder for Oral Suspension versus Cholestyramine Powder for Oral Suspension: Comparison of Acceptability and Tolerability. Endocr Pract. 2010 Nov 1:1-23.

Bays HE, Conard SE, Leiter LA, Bird SR, Lowe RS, Tershakovec AM. Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease. Int J Cardiol. 2010 Sep 11. [Epub ahead of print]

Bays HE, Roth EM, McKenney JM, Kelly MT, Thakker KM, Setze CM, Obermeyer K, Sleep DJ. The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia. Diabetes Care. 2010 Sep;33(9):2113-6

Bays H. Phentermine, topiramate, and their combination for the treatment of adiposopathy ("sick fat") and metabolic disease. Expert Rev. Cardiovasc. Ther. 2010; 8(12):1777-801.

Abstract: Positive caloric balance often causes pathologic adipocyte and adipose tissue anatomical and functional changes (termed adiposopathy or 'sick fat'), which may lead to pathogenic adipocyte and adipose tissue responses and metabolic disease. Fat weight loss may improve adiposopathy, and thus improve metabolic disease in overweight patients. Unfortunately, the efficacy of nonsurgical weight loss therapies is often limited due to redundant physiological systems that help 'protect' against starvation and/or negative caloric balance. One strategy to overcome these limitations is to combine weight loss drug therapies having complementary mechanisms of action, thereby affecting more than one physiologic process influencing body fat accumulation. Phentermine is a noradrenergic sympathomimetic amine approved for short-term treatment of obesity. Topiramate is a sulfamate-substituted monosaccharide derivative of the naturally occurring sugar monosaccharide d-fructose approved as treatment for migraine headaches and seizure disorders. Although known to facilitate weight loss since its approval, topiramate monotherapy does not have a regulatory indication as an anti-obesity agent. Phentermine HCl / topiramate controlled-release (PHEN/TPM CR) is a combination agent containing immediaterelease phentermine and controlled-release topiramate. Clinical trials involving thousands of patients demonstrate PHEN/TPM CR to be effective in improving the weight of patients, and also effective in improving adiposopathy-associated metabolic diseases. This review examines the pathophysiology of adiposopathy as a contributor to metabolic disease, the data supporting phentermine monotherapy, topiramate monotherapy and their combination as anti-obesity and anti-adiposopathy agents, and the preliminary evidence supporting PHEN/TPM CR as a generally well-tolerated and effective agent to improve metabolic disease.[CLICK HERE FOR A FREE DOWNLOAD OF THIS ARTICLE]

McKenney J, Bays H, Koren M, Ballantyne CM, Paolini JF, Mitchel Y, Betteridge A, Kuznetsova O, Sapre A, Sisk CM, Maccubbin D. Safety of Extended-Release Naicn/Laropiprant in Patients with Dyslipidemia. Journal of Clinical Lipidology. 2010;4:105 - 112.

Bays H, Maki K, McKenney J, Snipes R, Meadowcroft A, Schroyer R, Doyle R, Stein E. Long-term up to 24 month efficacy and safety of concomitant prescription omega-3 fatty acid ethyl esters and simvastatin in hypertriglyceridemic patients. Current Medical Research & Opinion (CMRO) Vol. 26, No. 4, 2010, 907–915

Bays HE, McKenney J, Maki KC, Doyle RT, Carter RN, Stein E. Bays HEffects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. Mayo Clin Proc. 2010 Feb;85(2):122-8.

Conard S, Bays H, Leiter LA, Bird S, Lin J, Hanson ME, Shah A, Tershakovec AM. Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes, Obesity and Metabolism. 2010 12;3:210-218.

Bays, H. E. and Ballantyne, C. What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush? Curr.Opin.Lipidol. 2009;20:467-476.

Bays HE. Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for ‘sick fat’ and metabolic disease. Expert Rev. Cardiovasc. Ther. 7(11), 1429–1445 (2009)

Abstract: Agonists of 5-hydroxytryptamine (5-HT; serotonin) receptors promote loss of excessive body fat (adiposity) and improve metabolic parameters associated with adiposity-induced adipose tissue dysfunction (adiposopathy or ‘sick fat’). By improving adipose tissue pathogenic endocrine and immune responses in overweight patients, 5-HT receptor agonists may improve metabolic disease. Lorcaserin (APD-356) is a selective 5-HT2c receptor agonist that promotes weight loss. Probably owing to its selectivity for the 5-HT2c receptor, clinical trial evidence supports that lorcaserin does not adversely affect heart valves or pulmonary artery pressure. This review examines: the mechanisms by which serotonergic pathways improve adiposity and adiposopathy; historical data and perspective regarding the efficacy and safety of prior 5-HT agonists; speculation regarding future paradigms in treating adiposopathy; and why lorcaserin may prove to be a safe and generally well-tolerated agent that not only improves the weight of patients, but also improves the health of patients. [CLICK HERE FOR A FREE DOWNLOAD OF THIS ARTICLE]

Bays HE, Maki KC, Schmitz K. The Bile Acid Sequestrant Acceptability scale validation study. Int J Clin Pract. 2010 Sep;64(10):1393-7. Epub 2010 Jul 5.

Bays, H. E., Maki, K. C., Doyle, R. T., and Stein, E. The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels. Postgrad.Med. 121(5), 145-150 (2009)

Bays HE, Laferrere B, Dixon J, Arrone L, Gonzalez-Campoy JM, Apovian C, Wolfe BM. "Adiposopathy and bariatric surgery: is 'sick fat' a surgical disease?" Consensus. Int J Clin Pract Sept. 2009 63(9) 1285-1300

Objective: To review how bariatric surgery in obese patients may effectively treatadiposopathy (pathogenic adipose tissue or ‘sick fat’), and to provide clinicians arationale as to why bariatric surgery is a potential treatment option for overweightpatients with type 2 diabetes, hypertension, and dyslipidaemia. Methods: A groupof clinicians, researchers, and surgeons, all with a background in treating obesityand the adverse metabolic consequences of excessive body fat, reviewed the medicalliterature regarding the improvement in metabolic disease with bariatric surgery. Results: Bariatric surgery improves metabolic disease through multiple, likelyinterrelated mechanisms including: (i) initial acute fasting and diminished caloricintake inherent with many gastrointestinal surgical procedures; (ii) favourable alterationsin gastrointestinal endocrine and immune responses, especially with bariatricsurgeries that reroute nutrient gastrointestinal delivery such as gastric bypass procedures;and (iii) a decrease in adipose tissue mass. Regarding adipose tissuemass, during positive caloric balance, impaired adipogenesis (resulting in limitationsin adipocyte number or size) and visceral adiposity are anatomic manifestationsof pathogenic adipose tissue (adiposopathy). This may cause adverse adiposetissue endocrine and immune responses that lead to metabolic disease. A decreasein adipocyte size and decrease in visceral adiposity, as often occurs with bariatricsurgery, may effectively improve adiposopathy, and thus effectively treat metabolicdisease. It is the relationship between bariatric surgery and its effects upon pathogenicadipose tissue that is the focus of this discussion. Conclusions: In selectiveobese patients with metabolic disease who are refractory to medical management,adiposopathy is a surgical disease. [CLICK HERE FOR A FREE DOWNLOAD OF THIS ARTICLE]

Bays HE. "Sick fat," metabolic disease, and atherosclerosis. Am J Med. 2009; 122 (1 Suppl) S26-37.

Abstract: Atherosclerotic coronary heart disease (CHD) is the most common cause of morbidity and mortality among men and women in developed nations. The obesity epidemic contributes to the increasing prevalence of high blood sugar (as may be found in patients with diabetes mellitus and metabolic syndrome), high blood pressure, and dyslipidemia--all CHD risk factors. Metabolic syndrome describes the common clinical finding wherein component CHD risk factors cluster within a single patient, but this term does not identify any unified pathophysiologic process. However, a component of the metabolic syndrome is abdominal obesity, which does reflect an anatomic manifestation of a "common-soil" pathophysiologic process that promotes the onset of CHD risk factors, and thus increases CHD risk. Adiposopathy ("sick fat") is anatomically characterized by visceral adiposity and adipocyte hypertrophy; it is manifested physiologically by a net increase in release of free fatty acids and by pathogenic adipose tissue metabolic/immune responses that promote metabolic disease and increase CHD risk. Understanding the relation of adiposopathy to CHD risk factors and recognizing the importance of treating both the "cause and effect" of metabolic diseases are critical toward a comprehensive approach in reducing CHD risk. Regarding the "cause," clinicians and their patients should be diligent regarding appropriate nutritional and lifestyle interventions that may favorably affect health. Regarding the "effect," clinicians and their patients should be equally diligent toward appropriate pharmaceutical interventions that reduce CHD risk factors when nutritional and lifestyle interventions do not sufficiently achieve desired metabolic treatment goals. [CLICK HERE FOR A FREE DOWNLOAD OF THIS ARTICLE]

Michael H. Davidson, MD, Kevin C. Maki, PhD, Harold Bays, MD, Roderick Carter, MD, MSc†, Christie M. Ballantyne, MD. Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia. Journal of Clinical Lipidology (2009) 3, 332–340.

Roth EM, Bays HE, Forker AD, Maki KC, Carter R, Doyle RT, Stein EA. Prescription Omega-3 Fatty Acid as an Adjuct to Fenofibrate Therapy in Hypertriglyceridemic Subjects. J Cardiovasc Pharmacol September 2009;54 (3) 196 - 203.

Bays HE, Maccubbin D, Meehan AG, Kuznetsova O, Mitchel YB, Paolini JF. Blood pressure-lowering effects of extended-release nacin/laropiprant combination: A post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients. Clin ther. 2009;1:115-22.

Bays H. Review of ARBITER 2: extended-release niacin added to statin therapy slows the progression of atherosclerosis. Commentary. Postgrad Med 2009 March;121(2):195-8.

Dall TL, Bays H. Addressing lipid treatment targets beyond cholesterol: a role for prescription omega-3 fatty acid therapy. SMJ. 2009 102;4:390-6

Goldberg AC, Bays HE, Ballantyne CM, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC. Efficacy and Safety of ABT-335 (Fenofibric Acid) in Combination With Atorvastatin in Patients With Mixed Dyslipidemia. Am J Cardiol. 2009;103:515-522.

Bays HE, Gonzalez-Campoy JM, Henry RR, Bergman DA, Schorr AB, Rodbard. Is adiposopathy ("sick fat") an endocrine disease? Int J Clin Pract. 2008:10:1474-83.

Abstract: OBJECTIVE: To review current consensus and controversy regarding whether obesity is a 'disease', examine the pathogenic potential of adipose tissue to promote metabolic disease and explore the merits of 'adiposopathy' and 'sick fat' as scientifically and clinically useful terms in defining when excessive body fat may represent a 'disease'. METHODS: A group of clinicians and researchers, all with a background in endocrinology, assembled to evaluate the medical literature, as it pertains to the pathologic and pathogenic potential of adipose tissue, with an emphasis on metabolic diseases that are often promoted by excessive body weight. RESULTS: The data support pathogenic adipose tissue as a disease. Challenges exist to convince many clinicians, patients, healthcare entities and the public that excessive body fat is often no less a 'disease' than the pathophysiological consequences related to anatomical abnormalities of other body tissues. 'Adiposopathy' has the potential to scientifically define adipose tissue anatomic and physiologic abnormalities, and their adverse consequences to patient health. Adiposopathy acknowledges that when positive caloric balance leads to adipocyte hypertrophy and visceral adiposity, then this may lead to pathogenic adipose tissue metabolic and immune responses that promote metabolic disease. From a patient perspective, explaining how excessive caloric intake might cause fat to become 'sick' also helps provide a rationale for patients to avoid weight gain. Adiposopathy also better justifies recommendations of weight loss as an effective therapeutic modality to improve metabolic disease in overweight and obese patients. CONCLUSION: Adiposopathy (sick fat) is an endocrine disease.[CLICK HERE FOR A FREE DOWNLOAD OF THIS ARTICLE]

Bays HE, Gonzalez-Campoy JM, Bray GA, Kitabchi AE, Bergman DA, Schorr AB, Rodbard HW, Henry RR.  Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity.  Expert Rev Cardiovasc Ther. 2008;3:343-368.

Abstract:  When caloric intake exceeds caloric expenditure, the positive caloric balance and storage of energy in adipose tissue often causes adipocyte hypertrophy and visceral adipose tissue accumulation. These pathogenic anatomic abnormalities may incite metabolic and immune responses that promote Type 2 diabetes mellitus, hypertension and dyslipidemia. These are the most common metabolic diseases managed by clinicians and are all major cardiovascular disease risk factors. 'Disease' is traditionally characterized as anatomic and physiologic abnormalities of an organ or organ system that contributes to adverse health consequences.  Using this definition, pathogenic adipose tissue is no less a disease than diseases of other body organs. This review describes the consequences of pathogenic fat cell hypertrophy and visceral adiposity, emphasizing the mechanistic contributions of genetic and environmental predispositions, adipogenesis, fat storage, free fatty acid metabolism, adipocyte factors and inflammation. Appreciating the full pathogenic potential of adipose tissue requires an integrated perspective, recognizing the importance of 'cross-talk' and interactions between adipose tissue and other body systems. Thus, the adverse metabolic consequences that accompany fat cell hypertrophy and visceral adiposity are best viewed as a pathologic partnership between the pathogenic potential adipose tissue and the inherited or acquired limitations and/or impairments of other body organs. A better understanding of the physiological and pathological interplay of pathogenic adipose tissue with other organs and organ systems may assist in developing better strategies in treating metabolic disease and reducing cardiovascular disease risk.  [CLICK HERE FOR A FREE DOWNLOAD OF THIS ARTICLE]

Bays HE. Practice Pearl: Commentary on Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extendedrelease niacin on atherosclerosis progression in secondary prevention patients treated with statins. The Physician and Sportsmedicine. 2008; 1: 129-131.

Bays HE, Jones PH, Mohiuddin SM, Kelly MT, Sun H, Setze3 CM, Buttler SM, Sleep DJ, Stolzenbach JC. Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. Journal of Clinical Lipidology 2008;2:426-435.

Bays HE, Gonzalez-Campoy JM, Henry RR, Bergman DA, Schorr AB, Rodbard. Is adiposopathy ("sick fat") an endocrine disease? Int J Clin Pract. 2008:10:1474-83.

Bays HE, Rader DJ. Does nicotinic acid (niacin) lower blood pressure? Int J Clin Pract January 2009;63:151–159.

Paolini JF, Bays HE, Ballantyne CM, Davidson M, Pasternak R, Maccubbin D, Morquist JM, Lai E, Waters G, Kuznetsova O, Sisk CM, Mitchel YB. Extended-Release Niacin/Laropiprant: Reducing Niacin-Induced Flushing to Better Realize the Benefit of Niacin in Improving Cardiovascular Risk Factors. Cardiology Clinics. 2008;26:547-560.

Bays H, Sapre A, Taggart W, Liu J, Capece R, Tershakovec A. Long-term (48-week) safety of ezetimibe 10 mg / day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia. Curr Med Res Opin 2008;24:2953-66

Conard SE, Bays HE, Leiter LA, Bird SR, Rubino J, Lowe RS, Tomassini JE, Tershakovec AM. Efficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) Versus Uptitration of Atorvastatin (to 40 mg) in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease. Am J Cardiol. 2008 Dec 1;102(11):1489-94

Leiter LA, Bays H, Conard S, Bird S, Rubino J, Hanson ME, Tomassini JE, Tershakovec AM. Efficacy and Safety of Ezetimibe Added on to Atorvastatin (40 mg) Compared With Uptitration of Atorvastatin (to 80 mg) in Hypercholesterolemic Patients at High Risk of Coronary
Heart Disease. Am J Cardiol. 2008 Dec 1;102(11):1495-501

Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam Hydrochloride Therapy in Patients With Type 2 Diabetes Mellitus Treated With Metformin: Glucose and Lipid Effects Arch Intern Med. 2008;168(18):1975-1983.

Maccubbin D, Bays HE, Olsson AG, Elinoff V, Elis A, Mitchel Y, Sirah W, Betteridge A, Reyes R,. Yu Q, Kuznetsova O, Sisk CM, Pasternak RC, Paolini JF. Lipid-modifying efficacy and tolerability of extended-release niacin⁄laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. International Journal of Clinical Practice 2008;62:1959-1970

Bays H. Rationale for prescription omega-3-acid ethyll ester therapy for hypertriglyceridemia: a primer for clinicians. Drugs Today. 2008;44:205-46

Jones PH, Bays HE, Davidson MH, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC. Evaluation of a New Formulation of Fenofibric Acid, ABT-335, Co-Administered with Statins : Study Design and Rationale of a Phase III Clinical Programme.Clin Drug Investig. 2008;28(10):625-34.

Paolini JF, Mitchel YB, Reyes R, Thompson-Bell S, Yu Q, Lai E, Watson DJ, Norquist JM, McCrary Sisk C, Bays HE.  Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire©: results from a randomised placebo-controlled clinical trial.  IJCP 2008; 62, 6, 896–904

Bays HE. Omega-3 Fatty Acids for Cardioprotection: Not Just Another Fish Story? Southern Medical Journal: Rapid Response 2008 http://www.sma.org/smj/rapidresponse/response_content.cfm?objectid=A2FE513A-1109-A387-6065412E60D18E96&responseID=A300BB35-1109-A387-6020084AA71FA8E4

Bays HE, Neff D, Tomassini JE, Tershakovec AM.  Ezetimibe:  Cholesterol lowering and beyond.  Expert Rev Cardiovasc Ther. 2008;4:447-70.

Bays HE, Gonzalez-Campoy JM, Bray GA, Kitabchi AE, Bergman DA, Schorr AB, Rodbard HW, Henry RR.  Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity.  Expert Rev Cardiovasc Ther. 2008;3:343-368.

Abstract:  When caloric intake exceeds caloric expenditure, the positive caloric balance and storage of energy in adipose tissue often causes adipocyte hypertrophy and visceral adipose tissue accumulation. These pathogenic anatomic abnormalities may incite metabolic and immune responses that promote Type 2 diabetes mellitus, hypertension and dyslipidemia. These are the most common metabolic diseases managed by clinicians and are all major cardiovascular disease risk factors. 'Disease' is traditionally characterized as anatomic and physiologic abnormalities of an organ or organ system that contributes to adverse health consequences.  Using this definition, pathogenic adipose tissue is no less a disease than diseases of other body organs. This review describes the consequences of pathogenic fat cell hypertrophy and visceral adiposity, emphasizing the mechanistic contributions of genetic and environmental predispositions, adipogenesis, fat storage, free fatty acid metabolism, adipocyte factors and inflammation. Appreciating the full pathogenic potential of adipose tissue requires an integrated perspective, recognizing the importance of 'cross-talk' and interactions between adipose tissue and other body systems. Thus, the adverse metabolic consequences that accompany fat cell hypertrophy and visceral adiposity are best viewed as a pathologic partnership between the pathogenic potential adipose tissue and the inherited or acquired limitations and/or impairments of other body organs. A better understanding of the physiological and pathological interplay of pathogenic adipose tissue with other organs and organ systems may assist in developing better strategies in treating metabolic disease and reducing cardiovascular disease risk.  [CLICK HERE FOR A FREE DOWNLOAD OF THIS ARTICLE]

Bays HE, Rodbard RW, Schorr AB, González-Campoy JM. Treating Pathogenic Adipose Tissue (Adiposopathy) to Reduce Cardiovascular Disease Risk. Current Treatment Options in Cardiovascular Medicine 2007 9;259-271

Abstract:  Excessive adipose tissue is potentially pathogenic due to its mass effects and through adverse metabolic/immune responses, which may lead to cardiovascular disease risk factors (eg, type 2 diabetes mellitus, hypertension, dyslipidemia, and possibly atherosclerosis itself). Positive caloric balance in genetically/environmentally susceptible patients may result in adipocyte hypertrophy, visceral adipose tissue accumulation, and ectopic fat deposition, all causally associated with metabolic disease, and all anatomic manifestations of “adiposopathy” (a term used to describe adipose tissue pathology). Weight loss through improved nutrition, increased physical activity, and weight loss agents (ie, orlistat and sibutramine) improves adiposopathy and improves many metabolic diseases whose prevalence are directly associated with an increase in body fat and sedentary lifestyle. Cannabinoid receptor antagonists improve adiposopathy through weight reduction and favorable metabolic effects upon multiple body organs (including adipocytes). Peroxisome proliferator-activated receptor-γ agonists may improve adiposopathy through recruitment of functional fat cells and apoptosis of dysfunctional fat cells.

Paolini JF, Mitchel YB, Reyes R, Uma Kher BA, Lai E, Watson DJ, Norquist JM, Meehan AG, Bays HE, Davidson M, Ballantyne CM.  Effects of Laropiprant on Nicotinic Acid-Induced Flushing in Patients with Dyslipidemia.  Am J Cardiol 2008;101:625-630.

Bays HE, Tighe AP, Sadovsky R, Davidson MH.  Prescription omega-3 fatty acids and their lipid effects:  physiological mechanisms of actions and clinical implications.  Expert Rev Cardiovasc Ther 2008;3:391-409.

Bays HE.  Safety of Niacin and Simvastatin Combination Therapy.  Am J Cardiol 2008;101[suppl]:3B-8B]

Bays HE, Chapman RH, Fox KM, Group SG.  Comparison of self-reported (SHIELD) versus NHANES data in estimating prevalence of dyslipidemia.  Curr Med Res Opin 2008

Bays HE, Goldberg RB.  The Forgotten Bile Acid Sequestrants: Is Now a Good Time to Remember?  American Journal of Therapeutics 14, 567–580 (2007)

Bays H, McElhattan J, Bryzinski BS; On Behalf of the Gallant 6 Study Group.  A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus.  Diab Vasc Dis Res 2007, 4(3):181-93

Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN.   Efficacy and Tolerability of Adding Prescription Omega-3 Fatty Acids 4g/d to Simvastatin 40 mg/d in Hypertriglyceridemic Patients:  An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study. Clinical Therapeutics 2007;29(7):1354-67.

Bays H, Jones PH. Colesevelam hydrochloride: Reducing atherosclerotic coronary heart disease risk factors. Vascular Health and Risk Management 2007;3(5):1-10.

Bays HE, Cohen DE.  Rationale and design of a prospective clinical trial program to evaluate the glucoselowering effects of colesevelam HCl in patients with type 2 diabetes mellitus.  Current Medical Research and Opinion Vol. 23 1673–1684 2007

Bays H, Blonde L, Rosenson R.  Adiposopathy:  how do diet, exercise, and weight loss drug therapies improve metabolic disease in overweight patients.  Expert Rev. Cardiovasc. Ther. 4(6), 871–895 (2006)  [CLICK HERE FOR A FREE DOWNLOAD OF THIS ARTICLE]

Abstract:  An increase in bodyweight is generally associated with an increased risk of excessive fat-related metabolic diseases (EFRMD), including Type 2 diabetes mellitus, hypertension and dyslipidemia. However, not all patients who are overweight have EFRMD, and not all patients with EFRMD are significantly overweight. The adipocentric paradigm provides the basis for a unifying, pathophysiological process whereby fat gain in susceptible patients leads to fat dysfunction (‘sick fat’), and wherein pathological abnormalities in fat function (adiposopathy) are more directly related to the onset of EFRMD than increases in fat mass (adiposity) alone. But just as worsening fat function worsens EFRMD, improved fat function improves EFRMD. Peroxisome proliferator-activated receptor-γ agonists increase the recruitment, proliferation and differentiation of preadipocytes (‘healthy fat’) and cause apoptosis of hypertrophic and dysfunctional (including visceral) adipocytes resulting in improved fat function and improved metabolic parameters associated with EFRMD. Weight loss interventions, such as a hypocaloric diet and physical exercise, in addition to agents such as orlistat, sibutramine and cannabinoid receptor antagonists, may have favorable effects upon fat storage (lipogenesis and fat distribution), nutrient metabolism (such as free fatty acids), favorable effects upon adipose tissue factors involved in metabolic processes and inflammation, and enhanced ‘cross-talk’ with other major organ systems. In some cases, weight loss therapeutic agents may even affect metabolic parameters and adipocyte function independently of weight loss alone, suggesting that the benefit of these agents in improving EFRMD may go beyond their efficacy in weight reduction. This review describes how adiposopathy interventions may affect fat function, and thus improve EFRMD.

Bays H, Ballantyne C.  Adiposopathy:  why do adiposity and obesity cause metabolic disease?  Future Lipidol. 2006 1(4), 389-420

Abstract: In the adipocentric paradigm, fat health affects patient health. Adiposopathy (‘pathos’ of adipose tissue or fat dysfunction) is more directly associated with excessive fat-related metabolic disease (EFRMD) than adiposity (increased fat mass) alone. Examples of adipocyte factors whose dysmetabolism may contribute to Type 2 diabetes mellitus include: 11 β-hydroxysteroid dehydrogenase type 1, acylation-stimulating protein, adiponectin, adipsin, angiotensinogen, autotaxin, ceramide, free fatty acids, hormone-sensitive lipase, interleukin-6, insulin-like growth factor-1, leptin, lipin, lysophospholipids, perilipin, phosphoenolpyrovate carboxykinase, plasminogen activator inhibitor-1, resistin, retinol-binding protein, tumor necrosis factor-α, visceral adipose tissue-derived serpin and visfatin. Excessive body fat may lead to hypertension due to physical compression of kidneys, sleep apnea, and other mechanisms. Examples of adipocyte factors whose dysmetabolism may contribute to hypertension include: 11 β-hydroxysteroid dehydrogenase type 1, adiponectin, angiotensinogen, angiotensin I and II, angiotensin-converting enzyme, renin, cathepsin, chymase, free fatty acids, interleukin-6 and leptin. Examples of adipocyte factors whose dysmetabolism may contribute to dyslipidemia include: 11 β-hydroxysteroid dehydrogenase type 1, acylation-stimulating protein, adipophilin, adiponectin, adipsin, cholesteryl ester-transfer protein, free fatty acids, hormone-sensitive lipase, leptin, lipoprotein lipase, perilipin, phospholipid transfer protein, sex hormones and tumor necrosis factor-α. Numerous other adipocyte factors may directly affect atherosclerosis and cardiomyopathy. A better understanding and recognition of how fat weight gain contributes to EFRMD will substantially affect the research and development of therapeutic interventions that may treat or prevent adiposopathy, and dramatically influence which patients with EFRMD are best treated and how.

Fox KM, Gandhi SK, Ohsfeldt RL, JW Blasetto, Bays HE.  Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL‑C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.  Current Medical Research and Opinion 23;9:2007, 2125–2133

Bays HE, Chapman RH, Grandy S.  The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys.  Int J Clin Pract, May 2007, 61, 5, 737–747  [Click here for a free download of this article]

Bays HE.  Safety considerations with omega-3 fatty acid therapy.  Am J Cardiol 2007;99[suppl]:35C-43C

Guyton JR, Bays HE.  Safety considerations with niacin therapy.  Am J Cardiol 2007;99[suppl]22C-31C

Bays HE.  Fish Oil Composition of Omacor and the GISSI Trial.  Am J Cardiol 2007;99:1483-1484

McKenney JM, Jones PH, Bays HE, Knopp RH, Kashyap ML, Ruoff GE, McGovern.  Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (COMPELL study).  Atherosclerosis 2007 Jun;192(2):432-7

Bays H, Rhyne J, Abby S, Lai, Yu-Ling L, Jones M.  Lipid-lowering effects of colesevelam HCl in combination with ezetimibe  Current Medical Research and Opinion 2006;22:2191–2200

Bays H.  Clinical Overview of Omacor:  A Concentrated Formulation of Omega-3 Polyunsaturated Fatty Acids.  Am J Cardiol.  2006;98:71i-76i.

Bays H, Ballantyne C.  Adiposopathy:  why do adiposity and obesity cause metabolic disease?  Future Lipidol. 2006 1(4), 389-420

Abstract: In the adipocentric paradigm, fat health affects patient health. Adiposopathy (‘pathos’ of adipose tissue or fat dysfunction) is more directly associated with excessive fat-related metabolic disease (EFRMD) than adiposity (increased fat mass) alone. Examples of adipocyte factors whose dysmetabolism may contribute to Type 2 diabetes mellitus include: 11 β-hydroxysteroid dehydrogenase type 1, acylation-stimulating protein, adiponectin, adipsin, angiotensinogen, autotaxin, ceramide, free fatty acids, hormone-sensitive lipase, interleukin-6, insulin-like growth factor-1, leptin, lipin, lysophospholipids, perilipin, phosphoenolpyrovate carboxykinase, plasminogen activator inhibitor-1, resistin, retinol-binding protein, tumor necrosis factor-α, visceral adipose tissue-derived serpin and visfatin. Excessive body fat may lead to hypertension due to physical compression of kidneys, sleep apnea, and other mechanisms. Examples of adipocyte factors whose dysmetabolism may contribute to hypertension include: 11 β-hydroxysteroid dehydrogenase type 1, adiponectin, angiotensinogen, angiotensin I and II, angiotensin-converting enzyme, renin, cathepsin, chymase, free fatty acids, interleukin-6 and leptin. Examples of adipocyte factors whose dysmetabolism may contribute to dyslipidemia include: 11 β-hydroxysteroid dehydrogenase type 1, acylation-stimulating protein, adipophilin, adiponectin, adipsin, cholesteryl ester-transfer protein, free fatty acids, hormone-sensitive lipase, leptin, lipoprotein lipase, perilipin, phospholipid transfer protein, sex hormones and tumor necrosis factor-α. Numerous other adipocyte factors may directly affect atherosclerosis and cardiomyopathy. A better understanding and recognition of how fat weight gain contributes to EFRMD will substantially affect the research and development of therapeutic interventions that may treat or prevent adiposopathy, and dramatically influence which patients with EFRMD are best treated and how.

Davidson MH, Bays HE, Stein E, Maki KC, Shalwitz RA, Doyle R, TRIMS Investigators.  Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects.  Clin Cardiol.  2006 Jun;29(6):268-73.

Bays HE.  Pharmacotherapeutic alternatives to optimize patients’ lipid profiles.  Today in Cardiology August 2006  pages 9-13. [CME Monograph]

Bays HE.  I was wrong.  Louisville Medicine.  2006;53:269

Bays HE, Davidson M, Jones MR, Abby SL.  Effects of Colesevelam Hydrochloride on Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein When Added to Statins in Patients With Hypercholesterolemia.  Am J Cardiol.  2006;97:1198-1205.

McKenney JM, Farnier M, Lo KW, Bays HE, Perevozkaya I, Carlson G, Davies MJ, Mitchel YB, Gumbiner B.  Safety and Efficacy of Long-Term Co-Administration of Fenofibrate and Ezetimibe in Patients With Mixed Hyperlipidemia. J Am Coll Cardiol, 2006; 47:1584-1587

Bays HE.  Statin safety: an overview and assessment of the data - 2005.  Am J Cardiol. 2006 Apr 17;97(8A):S6-S26. National Lipid Association (NLA) Statin Safety Supplement

Bays HE, Dujovne CA.  Adiposopathy is a More Rational Treatment Target for Metabolic Disease Than Obesity Alone.  Current Atherosclerosis Reports 2006, 8:144–156

Abstract:  Current guidelines recommend that weight-loss therapy should be primarily based upon specific body mass index (BMI) cut-off limits. However, in the adipocentric paradigm, it is acknowledged that co-morbidities, such as type 2 diabetes mellitus, hypertension, and dyslipidemia, occur at all levels of BMI.  Excessive fat mass (adiposity) in genetically susceptible individuals results in fat dysfunction (adiposopathy), which then contributes to metabolic disorders that increase the risk of atherosclerotic cardiovascular disease. In this paradigm, the term “anti-obesity” treatment might best be replaced by “anti-adiposopathy” treatment, wherein the focus is not based solely on BMI, but instead directed towards physiologically improving fat cell function and clinically improving the metabolic health of patients. This may occur through appropriate diet, physical exercise, and other lifestyle changes, and/or from drug therapies. Cannabinoid receptor antagonists and peroxisome proliferator activated receptor agonists are examples of agents that physiologically improve fat function and clinically improve metabolic disease.

Bays H.  What are the long-term effects of statin therapy?  Nat Clin Pract Cardiovasc Med 2006  Mar;3(3):128-9

Bays H, McKenney J, Davidson M.  Torcetrapib/atorvastatin combination therapy.  Expert Rev Cardiovasc Ther. 2005 Sep;3(5):789-820.

McKenney JM, Davidson MH, Saponaro J, Thompson PD, Bays HE; for the ATGOAL Investigators.  Us of a Treatment Algorithm to Achieve NCEP ATP III Goals with Atorvastatin.  J Cardiovasc Pharmacol.  2005 Nov;46(5):594-599.

Bays HE, McGovern ME.  Time as a Variable with Extended-Release/Lovastatin versus Atorvastatin and Simvastatin.  Prev Cardiol. 2005 Fall;8(4):226-33.

Davidson MH, Bays H, Rhyne J, Stein E, Rotenberg K, Doyle R.  Efficacy and Safety Profile of Fenofibrate-Coated Microgranules 130 mg, With and Without Food, in Patients with Hypertriglyceridemia and the Metabolic Syndrome:  An 8-Week, Randomized, Double Blind, Placebo-Controlled Study.  Clinical Therapeutics 2005 27;6:715-727.

Bays HE.  Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything.  Expert Rev. Cardiovasc. Ther. 3(3), 393–404 (2005)

Abstract:  Excessive fat (adiposity) and dysfunctional fat (adiposopathy) constitute the most common worldwide epidemics of our time – and perhaps of all time. Ongoing efforts to explain how the micro (adipocyte) and macro (body organ) biologic systems interact through function and dysfunction in promoting Type 2 diabetes mellitus, hypertension and dyslipidemia are not unlike the mechanistic and philosophical thinking processes involved in reconciling the micro (quantum physics) and macro (general relativity) theories in physics. Currently, the term metabolic syndrome refers to a constellation of consequences often associated with excess body fat and is an attempt to unify the associations known to exist between the four fundamental metabolic diseases of obesity, hyperglycemia (including Type 2 diabetes mellitus), hypertension and dyslipidemia. However, the association of adiposity with these metabolic disorders is not absolute and the metabolic syndrome does not describe underlying causality, nor does the metabolic syndrome necessarily reflect any reasonably related pathophysiologic process. Just as with quantum physics, general relativity and the four fundamental forces of the universe, the lack of an adequate unifying theory of micro causality and macro consequence is unsatisfying, and in medicine, impairs the development of agents that may globally improve both obesity and obesity-related metabolic disease. Emerging scientific and clinical evidence strongly supports the novel concept that it is not adiposity alone, but rather it is adiposopathy that is the underlying cause of most cases of Type 2 diabetes mellitus, hypertension and dyslipidemia. Adiposopathy is a plausible Theory of Everything for mankind’s greatest metabolic epidemics.  (All reprints should be obtained through Future Medicine).

Bays H.  Adiposopathy:  role of adipocyte factors in a new paradigm.  Expert Rev Cardiovasc Ther. 2005;3:187-9

Bays H.  Musliner T.  In response to ‘ezetimibe-induced hypertriglyceridemia’ case report.  (Letter to the Editor)  Int J Clin Pract, July 2005, 59, 7, 866–867.

Bays HE.  Combination therapy for global lipid improvement.  Hospital Pharmacy Europe 2005;May/June:1-3

Bays HE.  Combination Lipid-Altering Drug Therapy with Statins - Evolving Concepts in Lipid Management.  www.lipidsonline.org.  Updated January 2005.

Bays HE.  Collaborative Atorvastatin Diabetes Study (CARDS) - Commentary on Recent Publications  www.lipidsonline.org.  January 2005.

Bays H, Abate N, Chandalia M. Adiposopathy: Sick Fat Causes High Blood Sugar, High Blood Pressure, and Dyslipidemia. Future Cardiology (2005) 1(1), 39-59.

Abstract:  Adiposopathy is defined as pathological adipose tissue function that may be promoted and exacerbated by fat accumulation (adiposity) and sedentary lifestyle in genetically susceptible patients. Adiposopathy is a root cause of some of the most common metabolic diseases observed in clinical practice, including Type 2 diabetes mellitus, hypertension and dyslipidemia. The most common term for the metabolic consequences of adiposopathy is currently ‘the metabolic syndrome’. Drug usage to treat the metabolic syndrome has focused on the safety and efficacy of treatments directed towards individual components of the metabolic syndrome, and not so much upon adiposopathy itself. However, enough is known about the pathophysiology of adiposopathy to propose diagnostic criteria. Regulatory issues are important obstacles to the research and development of new drug treatments for the metabolic syndrome. It is hoped that these obstacles can, to some extent, be addressed and overcome by clearly defining and increasing our understanding of adiposopathy.  (NOTE:  This above article is copyrighted.  All reprints should be obtained through Future Medicine.)

Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R, Johnson-Levonas AO, Sapre A, Donahue SR, for the Ezetimibe Study Group.  A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Factorial Design Study to Evaluate the Lipid-Altering Efficacy and Safety Profile of the Ezetimibe/Simvastatin Tablet Compared with Simvastatin Monotherapy in Patients with Primary Hypercholesterolemia.  Clinical Therapeutics  Vol 26  No 11  2004  Pages 1758 - 1773.

Deedwania PC, Hunninghake DB, Bays HE, Jones PH, Cain VA, Blasetto JW, for the STELLAR Study Group:     Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.  Am J Cardiol 2005;95:360-366.

Deedwania PC, Hunninghake DB, Bays HE  Effects of lipid-altering treatment in diabetes mellitus and the metabolic syndrome.  Am J Cardiol - 3-JUN-2004; 93(11A): 18C-26C.

Bays HE.  Metabolic Sydrome:  What might be occurring?  Managed Care Supplement.  October 2004 Vol. 13 No 10.  Pages 13-16.

Bays H, Shepherd J.  Diabetes, Metabolic Syndrome and Dyslipidemia.  Management Strategies in Diabetes.  Cambridge Medical Publications.  ISBN 0 904052 88 5.  (2004) 1 - 28.

Deedwania PC, Hunninghake DB, Bays HE  Effects of lipid-altering treatment in diabetes mellitus and the metabolic syndrome.  Am J Cardiol - 3-JUN-2004; 93(11A): 18C-26C.

Bays H. Extended-release niacin/lovastatin: the first combination product for dyslipidemia. Expert Rev Cardiovasc Ther. 2004 Jul;2(4):485-501.

Bays H.  COMMENTARY:  Trial finds that simvastatin plus niacin is safe in people with coronary artery disease and low HDL cholesterol.  June 2004 Evidence-based Cardiovascular Medicine 2004 8:173–176

Bays H, Mandarino L, DeFronzo RA.  Role of the Adipocyte, FFA, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus.  Journal of Clinical Endocrinology and Metabolism 2004 89: 463-478.

Bays HE.  Combination Lipid-Altering Drug Therapy with Statins.  www.lipidsonline.org.  Published November 2003.

Bays HE, Stein EA. Pharmacotherapy for Dyslipidemia - Current Therapies and Future Agents. Expert Opinion on Pharmacotherapy. 2003, vol. 4, no. 11, pp. 1901 - 1938

Abstract:  Current lipid-altering agents that lower low density lipoprotein cholesterol (LDL-C) primarily through increased hepatic LDL receptor activity include statins, bile acid sequestrants/resins and cholesterol absorption inhibitors such as ezetimibe, plant stanols/sterols, polyphenols, as well as nutraceuticals such as oat bran, psyllium and soy proteins; those currently in development include newer statins, phytostanol analogues, squalene synthase inhibitors, bile acid transport inhibitors and SREBP cleavage-activating protein (SCAP) activating ligands. Other current agents that affect lipid metabolism include nicotinic acid (niacin), acipimox, high-dose fish oils, antioxidants and policosanol, whilst those in development include microsomal triglyceride transfer protein (MTP) inhibitors, acylcoenzyme A: cholesterol acyltransferase (ACAT) inhibitors, gemcabene, lifibrol, pantothenic acid analogues, nicotinic acid-receptor agonists, anti-inflammatory agents (such as Lp-PLA(2) antagonists and AGI1067) and functional oils. Current agents that affect nuclear receptors include PPAR-alpha and -gamma agonists, while in development are newer PPAR-alpha, -gamma and -delta agonists, as well as dual PPAR-alpha/gamma and 'pan' PPAR-alpha/gamma/delta agonists. Liver X receptor (LXR), farnesoid X receptor (FXR) and sterol-regulatory element binding protein (SREBP) are also nuclear receptor targets of investigational agents. Agents in development also may affect high density lipoprotein cholesterol (HDL-C) blood levels or flux and include cholesteryl ester transfer protein (CETP) inhibitors (such as torcetrapib), CETP vaccines, various HDL 'therapies' and upregulators of ATP-binding cassette transporter (ABC) A1, lecithin cholesterol acyltransferase (LCAT) and scavenger receptor class B Type 1 (SRB1), as well as synthetic apolipoprotein (Apo)E-related peptides. Fixed-dose combination lipid-altering drugs are currently available such as extended-release niacin/lovastatin, whilst atorvastatin/amlodipine, ezetimibe/simvastatin, atorvastatin/CETP inhibitor, statin/PPAR agonist, extended-release niacin/simvastatin and pravastatin/aspirin are under development. Finally, current and future lipid-altering drugs may include anti-obesity agents which could favourably affect lipid levels.  (NOTE:  This above article is copyrighted.  All reprints should be obtained through Ashley Publication Ltd.)

Bays HE, McGovern ME.  Once-Daily Niacin Extended-Release/Lovastatin Combination Tablet has More Favorable Effects on Lipoprotein Particle Size and Subclass Distribution Compared to Atorvastatin and Simvastatin.  Preventive Cardiology. 2003;6:179-188

Hunninghake DB, Stein EA, Bays HE, Rader DJ, Chitrae RR, Simonsone SG, Schnecke DW.   Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia.  Coronary Artery Disease.  2004, 15:115–123

Bays HE.  Atherogenic Dyslipidaemia in Type 2 Diabetes and Metabolic Syndrome: Current and Possible Future Treatment Options.  Br. J Diabetes Vasc Dis 2003;3(5)356-360

Bays HE.  Efficacy and Safety of Niacin Extended-Release/Lovastatin Compared With Atorvastatin and Simvastatin.  Cardiology Review October 2003;20(11) 34-38.

Bays HE, McKenney JM, Dujovne CA, Schrott HG, Zema MJ, Nyberg J, MacDougall DE, for the Gemcabene Study Group.  Effectiveness and Tolerability of a New Lipid-Altering Agent, Gemcabene, in Patients with Low Levels of High Density Lipoprotein-Cholesterol. Am J Cardiol 2003;92:538-543.

Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW.  Comparison of Efficacy and Safety of Rosuvastatin Versus Atorvastatin, Simvastatin, and Pravastatin Across Doses (STELLAR Trial).  Am J Cardiol. Volume 92, Issue 2 , 15 July 2003, Pages 152-160

Bays H, Dujovne C.  Colesevelam HCl:  A Non-Systemic Lipid Altering Drug.  Expert Opin. Pharmacotherapy  (2003) 4(5):779-790 

Isaacsohn J, Hunninghake D, Schrott H, Dujovne CA, Knopp R, Weiss SR, Bays H, Crouse JR, Davidson MH, Keilson LM, McKenney J, Korenman SG, Dobs AS, Stein E, Krauss RM, Maccubbin D, Cho M, Plotkin DJ, Mitchel Y. Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. Clin Cardiol 2003;26:18-24.

Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ, LeBeaut AP, Suresh R, Yang B, Veltri EP.  Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia.  Eur Heart J - April 15, 2003; 24(8); 729-741

Bays HE, Dujovne CA, McGovern ME, White TE, Kashyap ML, Hutcheson AG, Crouse JR.  Comparison of Once-Daily, Niacin Extended-Release / Lovastatin With Standard Doses of Atorvastatin and Simvastastin (The Advicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE].  Am J Cardiol  Vol. 91.  March 15, 2003:667-672.

Rosenson RS, Bays HE.  Results of Two Clinical Trials on the Safety and Efficacy of Pravastatin 80 and 160 mg Per Day.  Am J Cardiol Vol. 91 April 1, 2003:878-881.

Bays HE.  Ezetimibe - A Viewpoint by Harold Bays.  American J Cardiovasc Drugs 2003:3(1): 77.

Brown WV, Bays HE, Hassman DR, McKenney J, Chitra R, Hutchinson H, Miller E for the Rosuvastatin Study Group. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial. Am Heart J 2002;144:1036-43.

Bays HE. Ezetimibe. Expert Opin Investig Drugs. 2002 Nov; 11(11):1587-604.

Gagne C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, Cho M, Musliner TA, Gumbiner B, for the Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1084-1091.

Bays HE, Stein EA, Shah AK, Maccubbin DL, Mitchel YB, Mercuri M. Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients. Am J Cardiol. 2002 Nov 1:90(9):942-6.

Bays HE. Existing and Investigational combination drug therapy for high-density lipoprotein cholesterol. Am J Cardiol 2002;90(suppl):30K-43K.

Kashyap ML; McGovern ME; Berra K; Guyton JR; Kwiterovich PO; Harper WL; Toth PD; Favrot LK; Kerzner B; Nash SD; Bays HE; Simmons PD Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol - 15-Mar-2002; 89(6): 672-8

Bays HE; Moore PB; Drehobl MA; Rosenblatt S; Toth PD; Dujovne CA; Knopp RH; Lipka LJ; Lebeaut AP; Yang B; Mellars LE; Cuffie-Jackson C; Veltri EP Ezetimibe Study Group Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther - 01-Aug-2001; 23(8): 1209-30

Brown WV, McKenney JM, Zedler BK, Bays HE, Hassman HA, Caplan RJ, Miller E. A 52 Week Trial of Rosuvastatin Versus Pravastatin and Simvastatin in Patients with Primary Hypercholesterolemia.  XIV International Symposium on Drugs Affecting Lipid Metabolism, New York, New York, 9-12 September 2001.  Int J Clin Pract  2002;Suppl 124:12.

Dujovne CA; Bays H; Davidson MH; Knopp R; Hunninghake DB; Stein EA; Goldberg AC; Jones P; Lipka LJ; Cuffie-Jackson C. Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study. J Clin Pharmacol - 01-Jan-2001; 41(1): 70-8

Davidson MH; Stein EA; Hunninghake DB; Ose L; Dujovne CA; Insull W Jr; Bertolami M; Weiss SR; Kastelein JJ; Scott RS; Campod¢nico S; Escobar ID; Schrott HG; Bays H; Stepanavage ME; Wu M; Tate AC; Melino MR; Kush D; Mercuri M; Mitchel YB. Worldwide Expanded Dose Simvastatin Study Group Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia.  Nutrition Metabolism & Cardiovascular Diseases (2000); 10(5): p. 253-62.

Dobs AS; Schrott H; Davidson MH; Bays H; Stein EA; Kush D; Wu M; Mitchel Y; Illingworth RD Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism - 01-Sep-2000; 49(9): 1234-8

Stein E; Plotkin D; Bays H; Davidson M; Dujovne C; Korenman S; Stepanavage M; Mercuri M. Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia. Am J Cardiol - 15-Aug-2000; 86(4): 406-11

Bays HE; Dujovne CA Lipid-altering drugs in development. Drugs R D - 01-Jun-1999; 1(6): 463-9

Bays HE.  Lipid-Altering Drugs - Present and Future.  Louisville Medicine.  July 1999.  pp.  67 - 68.

Stein EA, Davidson MH, Dobs AS, Schrott H, Dujovne CA, Bays HE, Weiss SR, Melino MR, Stepanavage ME, Mitchel YB. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group. Am J of Cardiol. Mar 1;83(5):311-6, 1998 Aug 1.

Schrott H, Fereshetian AG, Knopp RH, Bays H, Jones PH, Littlejohn TW 3rd, McLain R, Black DM. A Multicenter, Placebo-Controlled, Dose-Ranging Study of Atorvastatin.  J Cardiovasc Pharmacol Ther. 1998 Apr;3(2):119-124.

Bays HE; Dujovne CA Drug interactions of lipid-altering drugs. Drug Saf - 01-Nov-1998; 19(5): 355-71

Y.B. Mitchel, M.E. Stepanavage, E.A. Stein, M.H. Davidson, A.S. Dobs, H. Schrott, C.A. Dujovne, H. Bays, S.R. Weiss, M.R. Melino, Efficacy and Safety of Simvastatin 80 mg/day in Hypercholesterolemic Patients, The American Journal of Cardiology 82 (3) (1998) pp. 311-316.

Meyers DG, Bays HE. Short Term Efficacy and Safety of Pravastatin in Hypercholesterolemic Women. Journal of Women's Health. 1995;4:357-365.

Bays HE, Dujovne CA. Drug Treatment of Patients with High Cholesterol Blood levels and Other Dyslipidemias. Progress in Drug Research 1994;43:9-41.

Bays HE, Dujovne CA. Antioxidants in the Treatment of Atherosclerotic Disease. Journal of Clinical Investigations in Arteriosclerosis. 1993;5:30-39.

Bays HE, Dujovne CA. Management of Multiple Cardiovascular Risk Factors in Primary Care. Resident and Staff Physician 1994;40:1-28

Bays HE, Dujovne CA. The use of Antioxidants in Clinical Practice: Past, Present and Future. Choices in Cardiology 1994;8:6-8

Bays HE, Dujovne CA, Mays B. Lipoprotein (a) [Lp(a)] as the Single Treatable Risk Factor in Patients with Onset or Recurrence of Atherosclerotic Cardiovascular Disease. Journal of the KMA 1993;Nov:498-500

Bays HE, Lansing A; Fish Oil Treatment of Hypertriglyceridemia. Journal of the KMA 1994;92:105-108

Bays HE, Dujovne CA. Combination Therapy With HMG CoA Reductase Inhibitors and Gemfibrozil - Authors Reply. Heart Disease and Stroke 1993;2:260-262

Bays HE, Dujovne CA, Lansing AM; Drug Treatment of Dyslipidemias: Practical Guidelines for the Primary Care Physician. Heart Disease and Stroke 1992;1:357-365

Bays HE, Dujovne CA; Drug Therapy for Hyperlipidemia. Postgraduate Medicine. 1992;91:162-193.

 

ABSTRACTS

Peter P Toth, Harold Bays, Michel Farnier, Erin Jensen, Joanne Tomassini, Adam Polis, JoAnne Foody, Andrew Tershakovec. Variability of LDL-C Lowering Responses to Statin Therapy in Achievement of ACC/AHA Target Levels. Abstract 10832. Circulation. 2015;132:A10832

Toth, PP, Bays, HE, Farnier, M, Jensen, E, Tomassini, JE, Polis, A, Foody, J, Tershakovec, AM. Variability of LDL-C lowering responses to statin therapy in achievement of ACC/AHA target levels . American Heart Association - 88th Scientific Session. 2015;

John J Kastelein, Dean J Kereiakes, Christopher P Cannon, Harold E Bays, Pascal Minini, L. Veronica Lee, Jaman Maroni, and Michel Farnier. Additional LDL-C Reduction Achieved With Alirocumab Dose Increase on Background Statin. Abstract 17099:Circulation. 2015;132:A17099,

Harold E. Bays, Lawrence A. Leiter, Helen M. Colhoun, Desmond Thompson, Laurence Bessac, Robert Pordy, Peter P. Toth Alirocumab treatment effect on non-HDL-C: pooled analyses of ten Phase 3 trials in the ODYSSEY program. National Lipid Association Annual Scientific Session. June 9 - 14, 2015 Chicago Illinois USA


Peter P Toth MD, PhD, Harold E Bays MD, W Virgil Brown MD, Joanne E Tomassini PhD, Colin Wang, Adam B Polis MA, Andrew M Tershakovec MD, MPH .Cholesterol in Remnant-Lipoproteins as Measured by Different Methods. National Lipid Association Annual Scientific Session. June 9 - 14, 2015 Chicago Illinois USA

William G. Stirtan, PhD, Rene A. Braeckman, PhD, Harold E. Bays, MD, Christie M. Ballantyne, MD, Paresh N. Soni, MD, PhD, Rebecca A. Juliano, PhD Pharmacokinetic and Triglyceride-lowering Pharmacodynamic Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) Across Clinical Studies National Lipid Association Annual Scientific Session. June 9 - 14, 2015 Chicago Illinois USA

Harold Bays, Jonas Hallén, Runar Vige, Rong Zhou, David Fraser, Svein Olaf Hustvedt, David G. Orloff, John Kastelein. Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week proof-of-concept study International Society of Atherosclerosis. Podium/Oral presentation May 23-26. 2015 Amsterdam, The Netherlands.

Peter Toth, Harold E. Bays, Virgil Brown, Joanne E. Tomassini, Colin Wang, Adam B. Polis, Andrew Tershakovec. Cholesterol remnant lipoproteins as measured by differrent methods. International Society of Atherosclerosis. Poster presentation May 23-26. 2015 Amsterdam, The Netherlands.

Peter Jones, Harold Bays, Umesh Chaudhari, Robert Pordy, Christelle Lorenzato, Kathryn Miller, Jennifer Robinson. Pooled Safety and Adverse Events in Nine Randomized, Placebo-controlled, Phase 2 and 3 Clinical Trials of Alirocumab. American College of Cardiology 64th Annual Scientific Session. March 14 - 16, 2015 San Diego CA. USA (Podium/oral Presentation)

Peter P Toth MD, PhD, Harold E Bays MD, W Virgil Brown MD, Joanne E Tomassini PhD, Colin Wang, Adam B Polis MA, Andrew M Tershakovec MD, MPH. Cholesterol in Remnant-Lipoproteins as Measured by Different Methods. American College of Cardiology 64th Annual Scientific Session. March 14 - 16, 2015 San Diego CA. USA

C.M. Ballantyne I , HE. Bays2, R.A. Braeckmana, S. Philip4, W.G. Stirtan4, R. T. Doyle4, P.N. Soni5 R. Julian04. 1 Baylor College of Medicine, Houston, United States of America; 2 Louisville Metabolic and Atherosclerosis Research Center, Louisville, United States of America; 3 Consultant, Doylestown, United States of America; 4Amarin Pharma Inc., Bedminster, United States of America; 5 Consultant, Mystic, United States of America. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on apolipoprotein C-lll in patients from the MARINE and ANCHOR studies. Eur Heart J. 2015; 36(suppl 1): 287

Christie M Ballantyne, Harold Bays, Rene Braeckman, Sephy Philip, William Stirtan, Ralph Doyle, Paresh N Soni, Rebecca A Juliano - Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects on Remnant-Like Particle Cholesterol From the MARINE and ANCHOR Studies. J Clin Lipidol. 2015; 9: 463-4.

Peter P Toth MD, PhD, Harold E Bays MD, W Virgil Brown MD, Joanne E Tomassini PhD, Colin Wang, Adam B Polis MA, Andrew M Tershakovec MD, MPH. Differences in Methods of Remnant-like Protein Cholesterol Measurement. European Atherosclerosis Society 83rd Congress. 2015.

Peter P Toth MD, PhD1, Harold E Bays MD2, W Virgil Brown MD3, Joanne E Tomassini PhD4, Colin Wang4, Adam B Polis MA4, Andrew M Tershakovec MD, MPH4. Cholesterol in remnant-lipoproteins as measured by different methods . International Symposium on Atherosclerosis - XVII. 2015;online:0182.

13.   Toth P, Tomassini J, Polis A, Tershakovec A, Bays H. Remnant cholesterol methods. Great Wall International Congress of Cardiology - 26th. 2015.

Peter P Toth MD, PhD1, Harold E Bays MD2, W Virgil Brown MD3, Joanne E Tomassini PhD4, Colin Wang4, Adam B Polis MA4, Andrew M Tershakovec MD, MPH4. Cholesterol in remnant-lipoproteins as measured by different methods . International Symposium on Atherosclerosis - XVII. 2015;online:0182.

Peter P Toth MD, PhD, Harold E Bays MD, W Virgil Brown MD, Joanne E Tomassini PhD, Colin Wang, Adam B Polis MA, Andrew M Tershakovec MD, MPH. Differences in Methods of Remnant-like Protein Cholesterol Measurement. European Atherosclerosis Society 83rd Congress. 2015;

Harold Bays, Louisville Metabolic and Atherosclerosis Res Ctr (L-MARC), Louisville, KY; Michel Farnier, Point Médical, Dijon, France; Daniel Gaudet, Univ de Montréal, Chicoutimi, QC, Canada; Robert Weiss, Maine Res Associates, Auburn, ME; Juan Lima Ruiz, Univry Hosp Vall d' Hebron, Barcelona, Spain; Gerald F Watts, Lipid Disorders Clinic, Royal Perth Hosp, Sch of Med and Pharmacology, Univ of Western Australia, Crawley, Australia; Ioanna Gouni-Berthold, Univ of Cologne, Cologne, Germany; Jennifer G Robinson, Univ of Iowa, Iowa City, IA; Peter H Jones, Baylor Coll of Med, Houston, TX; Randall Severance, Radiant Res - Phoenix SE, Chandler, AZ; Maurizio Averna, Univ di Palermo – Policlinico “Paolo Giaccone”, Palermo, Italy; Elisabeth Steinhagen-Thiessen, Charité - Univsmedizin Berlin Campus Virchow Klinikum, Berlin, Germany; Helen M Colhoun, Univ of Dundee, Dundee, United Kingdom; Jian Zhao, Regeneron Pharmaceuticals, Inc, Tarrytown, NY; Yunling Du, Regeneron Pharmaceuticals, Inc, Basking Ridge, NJ; Corinne Hanotin, Sanofi, Paris, France; Stephen Donahue, Regeneron Pharmaceuticals, Inc, Tarrytown, NY.  Efficacy and Safety of Combining Alirocumab With Atorvastatin or Rosuvastatin versus Statin Intensification or Adding Ezetimibe in High Cardiovascular Risk Patients: ODYSSEY OPTIONS I and II. American Heart Association Scientific Sessions November 15 - 19 2014 Chicago Illinois USA. (Podium/oral Presentation)

Harold Bays, Louisville Metabolic and Atherosclerosis Res Ctr (L-MARC), Louisville, KY; Daniel Gaudet, Univ de Montréal, Chicoutimi, QC, Canada; Robert Weiss, Maine Res Associates, Auburn, ME; Juan Lima Ruiz, Univ Hosp Vall d' Hebron, Barcelona, Spain; Gerald F Watts, Royal Perth Hosp, Crawley, Australia; Ioanna Gouni-Berthold, Univ of Cologne, Cologne, Germany; Jennifer G Robinson, Univ of Iowa, Iowa City, IA; Jian Zhao, Regeneron Pharmaceuticals, Inc, Tarrytown, NY; Corinne Hanotin, Sanofi, Paris, France; Stephen Donahue, Regeneron Pharmaceuticals, Inc, Tarrytown, NY  16194 - PCSK9 Inhibitor Alirocumab as Add-on to Atorvastatin versus Other Lipid Treatment Strategies in Patients at High CVD Risk: ODYSSEY OPTIONS I. American Heart Association Scientific Sessions November 15 - 19 2014 Chicago Illinois USA

Christie M Ballantyne, Baylor Coll of Med, Houston, TX; Harold Bays, Louisville Metabolic and Atherosclerosis Res Ctr, Louisville, KY; Rene Braeckman, Formerly of Amarin Pharma Inc., Doylestown, PA; Sephy Philip, William Stirtan, Ralph Doyle, Amarin Pharma, Inc., Bedminster, NJ; Paresh N Soni, Formerly of Amarin Pharma, Inc., Mystic, CT; Rebecca A Juliano, Amarin Pharma, Inc., Bedminster, NJ. 16803 - Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects on Remnant-Like Particle Cholesterol From the MARINE and ANCHOR Studies. American Heart Association Scientific Sessions November 15 - 19 2014 Chicago Illinois USA

Christie M. Ballantyne, MD, Harold E. Bays, MD, Rene A. Braeckman, PhD, William G. Stirtan, PhD, Ralph T. Doyle, Jr., BA, Rebecca Juliano, PhD, Paresh N. Soni, MD, PhD. Icosapent Ethyl (eicosapentaenoic acid ethyl ester): Effects on Apolipoprotein C-III in Patients
From the MARINE and ANCHOR Studies. National Lipid Association 2014 Annual Scientific Session May 1 - 4 Orlando Florida. 2014

Amy Larkin, PharmD, George Boutsalis, PhD, Colleen Healy, Harold Bays MD. Impact of Online CME on Improving Cardiologists' Knowledge Related to Omega-3 Fatty Acids. National Lipid Association 2014 Annual Scientific Session May 1 - 4 Orlando Florida. 2014

Christie M. Ballantvne. Joel Neutel, Anne Cropp, William Duggan, Ellen Wang, David Plowchalk, Kevin Sweeney, Nitin Kaila, John Vincent, Harold Bays, Baylor College of Medicine and Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA, Pfizer Inc., Groton and New York, NY, USA. EFFICACY AND SAFETY OF BOCOCIZUMAB (RN316/PF-04950615). A MONOCLONAL ANTIBODY AGAINST PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 IN STATIN-TREATED HYPERCHOLESTEROLEMIC SUBJECTS: RESULTS FROM A RANDOMIZED, PLACEBO-CONTROLLED. DOSE-RANGING STUDY (NCT: 01592240). March 30, 2014 .Clinical Presentation Number: 1183-129. American College of Cardiology Annual Session. New Orleans USA

Harold E. Bays, MD, Christie M. Ballantyne, MD, Rene A. Braeckman, PhD, William G. Stirtan, PhD, Paresh N. Soni, MD, PhD. High-sensitivity C-reactive Protein Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) With and Without Stable Statin Therapy in Hypertriglyceridemic Patients With Metabolic Syndrome. Presented at the Annual Scientific Sessions of the American Heart Association (AHA), November 16–20, 2013, Dallas, TX, USA.

Braeckman RA, Bays HE, Ballantyne CM, Stirtan WG, Soni PN. Pharmacokinetic and triglyceride-lowering pharmacodynamic effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) across clinical studies [poster]. Presented at the Annual Scientific Sessions of the American Heart Association, November 16-20, 2103, Dallas, Texas. USA

Eli M Roth, Ransi Somaratne, Michael Bolognese, Michael J Lillestol, Pernille Lundqvist, Harold Bays, Phillip D Toth, Jae B Kim, Jingyuan Yang, Scott M Wasserman, and Michael J Koren. Efficacy and Safety of Long-Term Treatment With AMG 145 Monotherapy. Encore presentation. Berne Hypertension Day Berne University, Switzerland 16 January 2014.

Eli M Roth, Ransi Somaratne, Michael Bolognese, Michael J Lillestol, Pernille Lundqvist, Harold Bays, Phillip D Toth, Jae B Kim, Jingyuan Yang, Scott M Wasserman, and Michael J Koren. Efficacy and Safety of Long-Term Treatment With AMG 145 Monotherapy. Presented at the Annual Scientific Sessions of the American Heart Association (AHA), November 16–20, 2013, Dallas, TX, USA.

Michael R. Jones, PhD; Harold E. Bays, MD; Soamnauth Misir, RPh, PharmD, MBA. Colesevelam HCl: glycemic and lipid parameter effects in patients with Type 2 diabetes mellitus treated with metformin-based therapy and a statin. Poster October 14, 2013. American College of Clinical Pharmacology Albuquerque New Mexico USA

Harold E. Bays, MD, FTOS, FACE, FNLA, Maurizio Averna, MD, Claudio Majul, MD, Dirk Muller-Wieland, MD, Annamaria De Pellegrin, MD, Hilde Giezek MSc, Raymond Lee, BS, Robert S. Lowe, PhD, Philippe Brudi, MD, Joseph Triscari, PhD, Michel Farnier, MD, PhD  Efficacy and Safety of Ezetimibe Added to Atorvastatin versus Atorvastatin Up-Titration or Switching to Rosuvastatin in Patients with Primary Hypercholesterolemia at High Cardiovascular Risk (the EZ-Switch Study).  Poster presented at the 2013 National Lipid Association (NLA) Annual Scientific Sessions, May 30–June 2, 2013, Las Vegas, NV, USA.

E.A. Stein, R. P. Giugliano, M. S. Sabatine, M. J. Koren, G. Langslet, H. Bays, D. Blom, M. Eriksson, R. Dent, S. M. Wasserman, F. Huang, T. Liu, M. Albizem, R. Scott, F. J. Raal.  Inhibition of PCSK9 with AMG 145, a Monoclonal Antibody, Reduces Lp(a): Insights from the Pooled PROFICIO Study  Poster  81st Congress of the European Atherosclerosis Society, Lyon, France, June 2-5, 2013

Christie M. Ballantyne, MD, Rene A. Braeckman, PhD, Harold E. Bays, MD, John J. Kastelein, MD, PhD, James D. Otvos, William G. Stirtan, PhD, Paresh N. Soni, MD, PhD. Effects of Icosapent Ethyl on Lipoprotein Particle Concentration and the Fatty Acid Desaturation Index in Statin-treated Patients With Persistent High Triglycerides (the ANCHOR Study)  Poster presented at the 2013 National Lipid Association (NLA) Annual Scientific Sessions, May 30–June 2, 2013, Las Vegas, NV, USA.

Michel Farnier, M. Averna, C. Majul, D. Muller-Wieland, A. De Pellegrin, H. Giezek, R. Lee, R.S. Lowe, P. Brudi, J. Triscari, H.E. Bays. Ezetimibe and atorvastatin coadministration versus atorvastatin up-titration or switching to rosuvastatin in patients with primary hypercholesterolemia and high cardiovascular risk. European Atherosclerosis Society meeting. Poster presentation. June 2nd - 5th. Lyon, France

X Ye, H Bays, J Swindle. Colesevelam HCl or  Ezetimibe for Hypercholesterolemia: Differences in Patient Characteristics from a Healthcare Database. American Heart Association Quality of Care and Outcomes Research 2013 Baltimore Maryland USA

Eliot A. Brinton, Christie M.. Ballantyne, Harold E. Bays, John J. Kastelein, Rene A. Braeckman, Paresh N. Soni.  629-P - Effects of Icosapent Ethyl on Lipid and Inflammatory Parameters in Patients with Diabetes Mellitus-2 and Residual Elevated Triglycerides (200-500 mg/dL) on Statin Therapy at LDL-C Goal: The ANCHOR Study. European Society of Cardiology Congress. August 25 - 29, 2012. Munich Germany

H. Bays, E.A. Brinton, J. Triscari, E. Chen, D. Maccubbin, A. MacLean, K. Gibson, A.O. Johnson-Levonas, Y.B. Mitchel. Extended-Release Niacin/Laropiprant Significantly Improves Lipid Levels in Type 2 Diabetes Mellitus Irrespective
of Baseline Glycemic Control. National Lipid Association Scientific Sessions. May 31 - June 3 2012. Scottsdale Arizona USA

Eliot A. Brinton, Christie M.. Ballantyne, Harold E. Bays, John J. Kastelein, Rene A. Braeckman, Paresh N. Soni.  629-P - Effects of AMR101 on Lipid and Inflammatory Parameters in Patients with Diabetes Mellitus-2 and Residual Elevated Triglycerides (200-500 mg/dL) on Statin Therapy at LDL-C Goal: The ANCHOR Study  American Diabetes Association Scientific Session.  June 8 – 12, 2012.  Philadelphia PA USA

Harold E. Bays, MD; Christie M. Ballantyne, MD; Rene A. Braeckman, PhD; William G. Stirtan, PhD; Paresh N. Soni, MD, PhD. AMR101, a Pure Ethyl Eicosapentaenoic Acid Omega-3 Fatty Acid: Effects on Inflammation-Associated End Points From the MARINE and ANCHOR Studies. National Lipid Association Scientific Sessions. May 31 - June 3 2012. Scottsdale Arizona USA

Joseph L Evans, Harold Bays, Kevin C Maki, Mal Evans, Veronique Maquet, Raymond Cooper, James W Anderson. Clinical Trials/Preventive Cardiology/Pharmaco Epidemiology: Abstract P307: Chitin-Glucan Fiber Effects on Oxidized Low-Density Lipoprotein: A Randomized Controlled Trial. Circulation. 2012;125:AP307.

CM Ballantyne, HE Bays, JJ Kastelein, E Stein, JL Isaacsohn, RA Braeckman, and PN Soni. AMR101 Lowers Triglycerides, Atherogenic Lipoprotein, Phospholipase A2, and High-sensitivity C-reactive Protein Levels in Patients With High Triglycerides and on Background Statin Therapy (the ANCHOR Study). National Lipid Association Scientific Sessions. May 31 - June 3 2012. Scottsdale Arizona USA

Bays HE, Jones MR. Colesevelam HCl: Glycemic and Lipid Parameter Effects in Patients with Type 2 Diabetes Mellitus (T2DM) Treated With Metformin-Based Therapy and a Statin. Podium/oral presentation American Association of Clinical Endocrinologists. 21st Annual Scientific and Clinical Congress. May 25 2012 Philadelphia PA USA

HE Bays, RA Braeckman, CM Ballantyne, JJ Kastelein, JD Otvos, WG Stirtan, and PN Soni. Effects of AMR101, a Pure-EPA Omega-3 Fatty Acid, on Lipoprotein Particle Concentration and Size in Patients with Very High Triglycerides (The MARINE Study). Podium/oral presentation American Heart Association 20th Scientific Session November 12 - 16 2011 Orlando Florida USA

CM Ballantyne, HE Bays,  JJ Kastelein, E Stein, JL Isaacsohn, RA Braeckman, PN Soni. AMR101 Lowers Triglycerides, Atherogenic Lipoprotein, Phospholipase A2, and High-sensitivity C-reactive Protein Levels in Patients With High Triglycerides and on Background Statin Therapy (the ANCHOR Study) Podium/oral presentation American Heart Association 20th Scientific Session November 12 - 16 2011 Orlando Florida USA

H. Bays, C. Ballantyne, J. Kastelein, E. Stein, J. Isaacsohn, R. Braeckman, P. Soni. AMR101, a pure-EPA omega-3 fatty acid, lowers triglycerides in patients with very high triglycerides without raising LDL-C: the MARINE Study. Podium/oral presentation European Society of Cardiology Congress August 27-31, 2011 Paris France

R. Braeckman, M. Manku, H. Bays, W. Stirtan, P. Soni. Effects of AMR101, a pure EPA omega-3 fatty acid, on the fatty acid profile in plasma and red blood cells in patients with very high triglycerides (results from the MARINE trial). Poster presentation. European Society of Cardiology Congress August 27-31, 2011 Paris France

Harold E. Bays, MD, FACP, FACE, FNLA; Christie M. Ballantyne, MD; John J. Kastelein, MD, PhD; Evan Stein, MD, PhD, FRCP; Jonathan L. Isaacsohn, MD, FACC; Rene A. Braeckman, PhD; and Paresh N. Soni, MD, PhD. AMR101, a Pure-EPA Omega-3 Fatty Acid, Lowers Triglycerides in Patients With Very High Triglycerides Without Raising LDL-C: The MARINE Study. Poster/Abstract Presentation. National Lipid Association. May 19-22, 2011. New York, New York. USA

Harold E. Bays, MD, Michael H. Davidson, MD; Rachid Massaad, MSc, Doreen Flaim, MS, Robert S. Lowe, PhD, Andrew M. Tershakovec, MD, MPH, Charlotte Jones-Burton, MD, MS. Efficacy and Safety of Ezetimibe Plus Rosuvastatin versus Rosuvastatin Up-Titration in Hypercholesterolemic Patients at Risk for Atherosclerotic Coronary Heart Disease. Poster/Abstract Presentation. National Lipid Association. May 19-22, 2011. New York, New York. USA

Harold Bays, Christie Ballantyne, Arvind Shah, Christine McCrary Sisk, Qian Dong, Darbie Maccubbin. The Lipid-Altering Effects of Extended Release Niacin/ Laropiprant are Consistent across Patient Subgroups. Poster/Abstract Presentation. National Lipid Association. May 19-22, 2011. New York, New York. USA

Harold E. Bays, MD; Ishwarlal Jialal, MD, PhD; Philip Levy, MD; Soamnauth Misir, PharmD; Michael R. Jones, PhD;
Kenneth E. Truitt, MD; Yehuda Handelsman, MD. Colesevelam Added to Background Metformin Therapy in Patients
with Type 2 Diabetes Mellitus: a Pooled Lipid Analysis from Three Clinical Studies. Oral/Podium Presentation. American Association of Clinical Endocrinologists 2011 Annual Meeting and Clinical Congress. April 14 2011. San Diego CA USA

Kevin C.Maki, Mary R. Dicklin, Susan L. Johnson, Mayadah Shabbout, Harold E. Bays. Prescription Omega-3 Fatty Acids Improve LDL Subclass Distribution without Increasing LDL Particle Concentration in Statin-Treated Patients withMixed Dyslipidemia Abstract/Poster Presentation April 2 – 5, 2011 American College Cardiology  New Orleans Louisiana USA

Harold E. Bays, Scott Conard, Lawrence A. Leiter, Steve Bird, Mary E. Hanson, Erin Jensen, Arvind Shah, Andrew M. Tershakovec. Are Post-treatment Low Density Lipoprotein Subclass Pattern Analyses Potentially Misleading? Poster Presentation. June 21 – 22, 2010.  European Atherosclerosis Society Congress.  Hamburg Germany

H. Bays, A. MacLean, A. Shah, Q. Dong, C. Sisk, D. Maccubbin. The Lipid-Altering Effects of Extended Release Niacin/Laropiprant are Consistent across Patient Subgroups. Poster Presentation. #134 May 15, 2010. National Lipid Association. Chicago Illinois USA

Harold E. Bays, Scott Conard, Lawrence A. Leiter, Steve Bird, Mary E. Hanson, Erin Jensen, Arvind Shah, Andrew M. Tershakovec. Are Post-treatment Low Density Lipoprotein Subclass Pattern Analyses Potentially Misleading? Poster Presentation. March 14, 2010. American College of Cardiology. Atlanta Georgia USA

Harold E. Bays, Eli M. Roth, Iain Dukes, Gloria Lin-Luo, Neil Cowen, Yu Liu, Essentialis, Inc., Carlsbad, CA. Diazoxide Choline Controlled Release in Hypertriglyceridemic Subjects: Lipid and Other Metabolic Effects. Poster Presentation. March 14, 2010. American College of Cardiology. Atlanta Georgia USA

Bays HE. Effect of prescription omega-3 fatty acids coadministered with escalating doses of atorvastatin on non-HDL-C in patients with hypertriglyceridemia. Poster presentation. American College of Clinical Pharmacology. October 18 - 21, 2009. Anaheim California USA

Bays HE. Long-term use of colesevelam HCl in subjects with type 2 diabetes mellitus (T2DM) on metformin therapy. Poster presentation. American College of Clinical Pharmacology. October 18 - 21, 2009. Anaheim California USA

Anton F H Stalenhoef, Michael N Davidson, Jennifer G Robinson, Regina Duttlinger-Maddux, David Kallend, Harold Bays. Dalcetrapib in high-risk patients with type 2 diabetes mellitus and/or metabolic syndrome. EASD meeting September 29 – October 2 2009. Poster Abstract. Vienna Austria.

Leiter LA, Conard S, Bays H, Lin J, Hanson ME, Shah A, Tershakovec AM. Comparative Efficacy of Ezetimibe Added to Atorvastatin vs Uptitration of Atorvastatin in Attainment of Recommended Lipid Targets in Patients at High Risk for Coronary Heart Disease (CHD). Poster Abstract. European Society of Cardiology. Aug 31st, 2009. Barcelona, Spain

A. MacLean, J. McKenney, R. Scott, E. Brinton, H. Bays, H. Giezek, R. Ruck, K. Gibson, C. McCrary Sisk, D. Maccubbin. Lipid-altering Efficacy and Tolerability of ER Niacin/Laropiprant in Patients with Type 2 Diabetes Mellitus. Poster Abstract. European Society of Cardiology. Aug 30, 2009. Barcelona, Spain

Bays HE, McKenney J, Doyle RT, Carter RN, Stein E. Prescription Omega-3s Coadministered with Atorvastatin for Patients with Hypertriglyceridemia. Poster Abstract. American Association of Diabetes Educators 36th Annual Meeting. August 5-8, 2009. Atlanta Georgia USA

E Meagher, M Davidson, M Rosen, J Robinson, H Bays, L Bloedon, W Sasiela, M Parris, D Rader Effects Of Low Dose Mtp Inhibition Alone And In Combination With Other Lipid-Lowering Drugs On Hepatic Fat And Plasma Lipids.  Abstract Poster #103 Presentation
XV International Symposium on Atherosclerosis  June 14-18 2009  Boston Massachusetts USA

H Bays, S Schwartz, T Littlejohn, B Kerzner, R Krauss, X Wang, Y Choi, D Karpf, B Roberts.  Mbx8025, A Novel Pparδ Agonist: Lipid & Metabolic Effects In Dyslipidemic Overweight Patients Abstract Oral/Podium Presentation XV International Symposium on Atherosclerosis  June 14-18  2009 Boston Massachusetts USA

H Bays, S Conard, L Leiter, E Jensen, A Shah, M Hanson, A Tershakovec Ezetimibe (E) Added To Atorvastatin (A): Effect On Lipoprotein Subclass Cholesterol Content In Patients With Higher Versus Lower Triglyceride Levels (TG) Abstract Poster #823 Presentation  XV International Symposium on Atherosclerosis  June 14-18  2009 Boston Massachusetts USA

H Bays, S Conard, L Leiter, S Bird, J Lin, R Lowe, A Shah, A Tershakovec.  Ezetimibe(E) + Atorvastatin (A) Vs. A Up-Titration In Moderately High CHD Risk (MHR) Or High CHD Risk (HR) Patients: Effects Of Baseline Body Mass Index (BMI), Fasting Blood Sugar (FBS) And HS-CRP  Abstract Poster #948 Presentation  XV International Symposium on Atherosclerosis  June 14-18  2009 Boston Massachusetts USA

H Bays, S Conard, L Leiter, S Bird, R Lowe, A Tershakovec Influence Of Age, Gender, And Race On The Efficacy Of Ezetimibe Plus Atorvastatin Vs. Atorvastatin Up-Titration In Moderately High/High Chd Risk Patients.  Abstract Poster #949 Presentation  XV International Symposium on Atherosclerosis  June 14-18  2009 Boston Massachusetts USA

H Bays, K Maki, J Mckenney, R Doyle, E Stein Long-Term Efficacy Of Prescription Omega-3 Fatty Acids Coadministered With Simvastatin In Hypertriglyceridemic Patients.  Abstract Poster # 950 Presentation  XV International Symposium on Atherosclerosis  June 14-18  2009 Boston Massachusetts USA

Bays HE, Davidson M, Schwartz SL, Price C, Sasiela WJ, Parris M, Meagher E, Rader D. Body Weight Reducitons with Low Dose Lomitapide (AEGR-733), a Microsomal Triglyceride Transfer Protein Inhibitor: Results from Three Phase 2 Trials. Abstract Poster Presentation #471. American Diabetes Association 69th Scientific Session June 5-9, 2009 New Orleans LA USA

Conard S, Bays H, Leiter L, Bird S, Lin J, Hanson M, Shah A, Tershakovec AM. Ezetimibe Added to Atorvastatin Compared with Titration of Atorvastatin in Patients at High Risk of Coronary Heart Disease with Diabetes Mellitus or Metabolic Syndrome. Abstract Poster Presentation #669. American Diabetes Association 69th Scientific Session June 5-9, 2009 New Orleans LA USA

Bays HE, Maki KC, Carter RN, Doyle RT, Stein E. Effect of Prescription Omega-3 Fatty Acids on Body Weight in Patients with Very High Triglyceride Levels. Abstract Poster Publication #2444. American Diabetes Association 69th Scientific Session June 5-9, 2009 New Orleans LA USA

Bays HE, Hansen ME, Jensen E, Shah A, Leiter L, Conard S, Tershakovec AM. Effect of Ezetimibe Added to Atorvastatin on Lipoprotein Subclass Cholesterol Content in Patients with Higher versus Lower Triglyceride Levels. National Lipid Association Abstract/Poster Presentation May 2, 2009 P218 Miami Beach Florida USA

Maki KC, Bays HE, McKenney J, Doyle RT, Carter RN, Stein E. Effects of Prescription Omega-3 Fatty Acids Co-administered With Escalating Doses of Atorvastatin on Lipoprotein Particle Sizes and Concentrations in Hypertriglyceridemic Patients 2009 ATVB Annual Conference Abstract/Poster Presentation April 29 - May 1 Washington DC USA

Conard SE, Leiter L, Bays H, Shah A, Lin J, Hanson ME, Tershakovec AM. Comparative Efficacy of Ezetimibe Added to Atorvastatin vs. Uptitration of Atorvastatin in Attainment of Recommended Lipid Targets in Patients at High Risk for Coronary Heart Disease. 2009 National Lipid Association Abstract/Poster Presentation May 2, 2009 P220 Miami Beach Florida USA

Bays HE, Conard S, Leiter LA, Bird S, Shah AK, Lin J, Lowe RS, Tershakovec AM. Does Baseline Body Mass Index, Fasting Blood Sugar and High-Sensity C-Reactive Protein Influence the Efficacy of Adding Ezetimibe to Atorvastatin versus Doubling the Atorvastatin Does in Moderately High and High Coronary Heart Disease Risk Patients. National Lipid Association Abstract/Poster Presentation May 2, 2009 P217 Miami Beach Florida USA

Davidson MH, Stalenhoef AFH, Robinson JG, Duttlinger-Maddux R, Kallend D, Bays H. Dalcetrapib in High-Risk Patients with Type 2 Diabetes Mellitus and/or Metabolic Syndrome. National Lipid Association Abstract/Poster Presentation May 2, 2009 P216 Miami Beach Florida USA

Bays HE, Conard S, Leiter LA, Bird S, Lowe RS, Tershakovec AM. Do Age, Gender, and Race Affect the Efficacy of Ezetimibe Plus Atorvastatin vs. Doubling the Atorvastatin Dose in Moderately High and High CHD Risk Patients. National Lipid Association Abstract/Poster Presentation May 2, 2009 P212 Miami Beach Florida USA

Maki K, Bays HE, McKenney J, Doyle RT, Carter RN, Stein E. Effects of Prescription Omega-3 Fatty Acids Co-administered With Escalating Doses of Atorvastatin on Lipoprotein Particle Sizes and Concentrations in Hypertriglyceridemic Patients. Arteriosclerosis, Thrombosis, and Vascular Biology Annual Conference Abstract/Poster Presentation May 1, 2009 P504 Washington DC USA

Bays HE, McKenney J, Doyle RT, Carter RN, Stein EA. Effect of Prescription Omega-3 Fatty Acids (P-OM3, Lovaza®) Coadministered With Escalating Doses of Atorvastatin in Patients With Hypertriglyceridemia. The American Heart Association Scientific Sessions. Oral/Podium Presentation. November 11, 2008 New Orleans, USA

Bays HE, Jones PH, Mohiuddin SM, Kelly MT, Sun J, Setze CM, Buttler SM, Sleep DJ, Stolzenbach JC. Long-Term Safety and Efficacy of ABT-335 (Fenofibric Acid) in Combination with Statin Therapy for the Treatment of Patients with Mixed Dyslipidemia. The American Heart Association Scientific Sessions. Abstract/Poster Presentation. November 11, 2008. New Orleans, USA

Grundy S, Davidson M, Bays H, Rosen M, Meagher E, Bloedon L, Price C, Parris M, Sasiela W, Rader D. Prevalence and Analysis of Hepatic Steatosis in Patients with Hypercholesterolemia who Lack Traditional Risk Factors Associated with Steatosis. 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Poster presentation. October 31 - November 4 2008. San Francisco USA

Bays H, Setze C, Kelly M, Gustafson K, Sleep D, Stolzenbach J. The effect of ABT-335 (Fenofibric Acid) on the prevalence of metabolic syndrome in patients with mixed dyslipidemia. Lorenzini: The 7th International Symposium on Multiple Risk Factors in Cardiovascular Disease. Oral/Podium Presentation. October 22, 2008 Venice (Lido) Italy

Bays HE, Maccubbin DL, Shah AK, Lin J, Sisk CM, Paolini JF. Lipid-altering efficacy of extended-release niacin/laropiprant in dyslipidaemic patients with metabolic syndrome. The European Assocation for the Study of Diabetes. Poster Presentation. Sept. 10, 2008 Rome Italy.

Bays HE, Setze CM, Kelly MT, Sun H, Sleep DJ, Stolzenbach JC. ABT-335 Effects upon Glucose Levels in Patients with Mixed (Atherogenic) Dyslipidemia and "Pre-Diabetes." The Endocrine Society 90th Annual Meeting Oral/Podium Presentation June 18th 2008 San Francisco USA

Bays HE, Maccubbin D, Shah A, Lin J, Sisk CM, Paolini JF. Lipid-Altering Efficacy of ER Niacin/Laropiprant in Dyslipidemic Patients with Metabolic Syndrome American Diabetes Association 68th Scientific Session Oral/Podium Presentation June 7, 2008 San Francisco USA

Bays HE, Abby SL, Jones MR. Dual Efficacy: A1c and LDL-C Lowering With Colesevelam HCl in Patients with Type 2 Diabetes Mellitus. Poster and Oral/Podium Presentation. National Lipid Association Scientific Session. May 31, 2008. Seattle Washington USA

Bays H, Truitt K, Jones M. The Glucose-Lowering Effects of Colesevelam HCl in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Based Therapy: A Pooled Analysis. Abstract #230. 17th Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists. May 14-18, 2008. Orlando Florida USA

McKenney J, Bays H, Koren MJ, Ballantyne C, Maccubbin D, Mitchel Y, Betterridge A, Kuznetsova O, Sapre A, Sisk CM, Paolini JF.  Safety Profile of Extended-Release Niacin/Laropiprant in Patients with Dyslipidemia.  77th European Atherosclerosis Society Congress.  Instanbul Turkey.  April 26-29, 2008

Bays H, Maccubbin D, Meehan A, Kuznetsova O, Mitchel Y, Paolini JF.  Blood Pressure-Lowering Effect of ER Niacin and ER Niacin/Laropiprant in Dyslipidemic Patients.  Presentation 1021-216.  Poster Presentation.  March 31, 2008  American College of Cardiology 57th Annual Scientific Session Chicago, Illinois, USA.

Goldberg AC, Bays HE, Ballantyne CM, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.   Efficacy and Safety of a Novel Fibrate, ABT-335, in Combination with Atorvastatin in Patients with Mixed Dyslipidemia:  A 12-week Phase 3 Study.  Presentation 1021-222 March 31, 2008.  American College of Cardiology 57th Annual Scientific Session Chicago, Illinois, USA.

McKenney J, Bays H, Koren MJ, Ballantyne C, Maccubbin D, Mitchel Y, Betterridge A, Kuznetsova O, Sapre A, Sisk CM, Paolini JF.  Safety Profile of Extended-Release Niacin/Laropiprant in Patients with Dyslipidemia.  Presentation 1028-168  March 31, 2008.  American College of Cardiology 57th Annual Scientific Session Chicago, Illinois, USA

Bays HE, Weiss RJ, Rhyne JM, Chen Y, Lopez C, Spezzi AH.  Lapaquistat Acetate Monotherapy:  Effects of a Novel Squalene Synthase Inhibitor on LDL-C Levels and Other Lipid Parameters in Patients with Primary Hypercholesterolemia.  Abstract # 682  Oral/Podium Presentation.  Circulation Vol 116, No 16, October 16, 2007  Presented at the American Heart Association, November 4 - 7, 2007, Orlando Florida USA

Davidson M, Maki KC, Doyle RT, Shalwitz B, Bays H, Stein EA.  Correlates of the Apolipoprotein C-III Response to the Addition of Prescription Omega-3 in Adults with Hypertriglyceridemia Despite Stable Statin Therapy.  Abstract #192.   Circulation Vol 116, No 16, October 16, 2007  Presented at the American Heart Association, November 4 - 7, 2007, Orlando Florida USA

Maccubbin D, Sirah W. Betteridge A, Kuznetsova O, Yu Q, Sisk CM, Bays H, Olsson AG, Pasternak RC, Mitchel Y, Paolini JF.  Flushing Profile of ER Niacin/Laropiprant in Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia.  Abstract #191.  Circulation Vol 116, No 16, October 16, 2007  Presented at the American Heart Association, November 4 - 7, 2007, Orlando Florida USA

Bays HE, Abby S, Truitt K, Jones MR.  Colesevelam HCl Reduces Cholesterol and Glucose Levels When Added to Metformin-Based Therapy in Patients with Type 2 Diabetes Mellitus.  Journal of Clinical Lipidology.  Vol 1, No 5, October 2007 Abstract #401 DALM October 4-7 New York, New York. USA

Paolini JF, Mitchel YB, Reyes R, Thompson-Bell S, Yu Q, Lai E, Watson DJ, Norquist JM, Sisk C, Bays H.  Measuring Niacin-Induced Flushing Using the Flushing Symptom Questionnaire.  Journal of Clinical Lipidology.  Vol 1, No 5, October 2007 Abstract #275 DALM October 4-7 New York, New York. USA

Bays H, Davidson M, Shalwitz R, Doyle R, Ballantyne C.  Prescription Omega-3 "Added On" to Stable Statin Therapy:  Changes in Lipid Parameters.  Journal of Clinical Lipidology.  Vol 1, No 5, October 2007 Abstract #178 DALM October 4-7 New York, New York. USA

Maccubbin D, Mitchel YB, Sirah W, Betteridge A, Yu Q, Sisk CM, Bays H, Olsson AG, Pasternak RC, Paolini JF.  Lipid-altering Efficacy and Flushing Profile of ER Niacin/Laropiprant in Patients with Dyslipidemia.  Journal of Clinical Lipidology.  Vol 1, No 5, October 2007 Abstract #38 DALM October 4-7 New York, New York. USA

Ballantyne CM, Bays H, Shalwitz R, Doyle RT, Davidson MH.  Prescription Omega-3 added to stable Statin Therapy:  A Mechanistic Perspective.  7th International Congress on Coronary Artery Disease.  Venice, Italy.  October 7-10, 2007.

Maccubbin DL, Mitchel Y, Sirah W, Betteridge A, Yu Q, Sisk CM, Bays H, Olsson AG, Pasternak RC, Paolini JF.  Lipid-altering Efficacy and Tolerability of Extended-release Niacin/Laropiprant in Patients with Dyslipidemia.  European Society of Cardiology (ESC) Vienna Austria September 1-5, 2007

Bays HE, Goldberg RB, Truitt K, Dmuchowski C, Jones MR.  Effect of Colesevelam HCl on Glycemic Control in Subjects with Type 2 Diabetes Mellitus Receiving Metformin Monotherapy   American Diabetes Association 485-P abstract.  67th Scientific Sessions.  Chicago Illinois June 24 2007

Goldberg RB, Bays HE, Truitt K, Dmuchowski C. Jones MR. Colesevelam HCl Improves the Lipid Profile in Subjects with Type 2 with Inadequate Glycemic Control on Metformin American Diabetes Association.  484-P abstract.  67th Scientific Sessions.  Chicago Illinois June 24 2007

Davidson MH, Bays HE, Stein EA, Maki KC, Farnier M, Doyle RT, Shalwitz RA.  Effects of Prescription Omega-3-Acid Ethyl Esters on Lipid Responses in Women with Hypertriglyceridemia Despite Statin Therapy.  P2-58.  The Endocrine Society 89th Annual Meeting.  Toronto Canada June 3, 2007.

Maki KC, Davidson MH, Bays HE, Stein EA, Shalwitz RA, Doyle R.  Effects of Omega-3-acid Ethyl Esters on LDL Particle Size in Subjects with Hypertriglyceridemia Despite Statin Therapy.  2007 FASEB Journal.  2007;21:231.2 

Bays HE, Goldberg RB.  Truitt K, Dmuchowski C, Jones MR.  Addition of Colesevelam HCl to Patients with Type 2 Diabetes Mellitus Inadequately Controlled on a Metformin-Based Therapy Improves Glycemic Control.  Poster Presentation Abstract #204.  AACE 16th Annual Meeting and Clinical Congress, Seattle Washington USA.  Friday, April 14th, 2007

Bays HE, Paolini JF, Norquist JM, Yu, Q, Watson DJ.  Measuring Niacin-Induced Flushing Using a Flushing Symptom Questionnaire.  Poster Presentation Abstract #204.  AACE 16th Annual Meeting and Clinical Congress, Seattle Washington USA.  Friday, April 13th, 2007

Fox KM, Gandhi SK, Ohsfeldt RL, Blasetto J, Bays HE.  Effectiveness of Rosuvastatin in LDL-C Lowering and National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Goal Attainment compared to other Statins among Diabetes Patients.  2448-PO  Diabetes - June Supplement.  67th Scientific Sessions Chicago Illinois USA (June 22 - 26) Abstract Book 2007

Paolini JF, Mitchel YB, Reyes R, Kher U, Lai E, Watson DJ, Norquist J, Meehan AG, Bays H, Davidson M, Ballantyne C.  Effects of the DP1-Receptor Antagonist MK-0524 on Nicotinic Acid-Induced Flushing in Lipid Clinic Patients.  AHA Scientific Sessions Chicago Illinois USA November 15, 2006

Bays H, Rhyne J, Abby S, Yu-Ling L, Jones M.  Lipoprotein Particle Size Effects of Colesevelam HCl in Combination with Ezetimibe and Simvastatin.  Abstract/Poster Presentation.  AHA Scientific Sessions Chicago Illinois USA November 13, 2006

Davidson MH, Bays H, Stein E, Maki KC, Doyle R, Shalwitz RA.  COMBOS:  Combination of prescription omega-3s with simvastatin:  a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of prescription omega-3 (Omacor) added to stable statin therapy in hypertriglyceridemic patients.  Poster abstract.  national Lipid Association Midwest 2006; October 20-22, Kansas City Missouri.

Bays HE, Chapman RH, Grandy S, and the SHIELD Study Group.  Prevalence of Dyslipidemia Estimated from a Self-Reported Survey Versus Clinical and Laboratory Evaluation:  Comparison of SHIELD and NHANES.  Abstract/Poster Presentation.  XIV International Symposium on Atherosclerosis.  Rome Italy June 19, 2006  (Atheroscler Suppl 2006;7(3):51-52  (Abstract Mo-P1:29).

McKenney JM, Jones PH, Bays HE, Knopp RH, Kashyap ML, Ruoff GE, Stanek EJ, McGovern ME. Comparative Lipid Effects of Combination Therapy with a Statin and Extended-Release Niacin Versus Statin Plus Ezetimibe Versus a Statin Alone. Abstract/Poster Presentation.  XIV International Symposium on Atherosclerosis.  Rome Italy June 19-23, 2006

Davies, M.J., Bays, H.E., Shah, A., Macdonell, G., Gumbiner, B.  Effects of co-administered ezetimibe and fenofibrate in mixed dyslipidaemic patients with metabolic syndrome.  Diabetologia 2006; 49 (Suppl. 1):452-453. 

Bays, H. E., Davies, M., Shah, A., Macdonell, G., Gumbiner, B.  Effects of co-administered ezetimibe (EZE) and fenofibrate(FENO) in mixed dyslipidemic patients with metabolic syndrome (METS). Diabetes 2006; 55 (Suppl. 1):A519

Bays HE, Rhyne J, Abby S, Lai Y, Jones M.  Lipid Lowering Effects of Colesevelam HCL in Combination with Ezetimibe.  Abstract/Poster Presentation.  April 27, 2006.  7th Annual Conference on Arteriosclerosis, Thrombosis, and Vascular Biology.  Denver CO.  USA

Bays HE, Jones MR, Abby SL.  Colesevelam HCL Added to Statin:  Effects Upon Lipid Profile and hs-CRP.  Abstract/Poster Presentation.  November 15, 2005.  American Heart Association.  2005 Scientific Sessions.  Dallas Texas USA

Bays HE, Stanek EJ, McGovern ME.  Once-daily, Extended-Release Niacin/Lovastatin Combination Improves Cholesterol and Apolipoprotein Ratios Compared with Atorvastatin and Simvastatin.  2nd International Symposium on Triglycerides and HDL:  Role in Cardiovascular Disease and the Metabolic Syndrome.  Oral/Podium Presentation  New York NY USA, July 17, 2005.

Bays H, Davidson MH, Stein EA, Rhyne JM, Rotenberg KS, Dole RT.  Efficacy and Safety of Micronized Fenofibrate-130 mg Taken With or Without Food Versus Placebo in Patient with Hypertriglyceridemia and Metabolic Syndrome - TRIMS Study (Triglyceride Reduction in Metabolic Syndrome)  Abstract/Poster #750.  Endocr Pract. 2005;11(Suppl 1) 1.  American Association of Clinical Endocrinologists.  Washington DC USA.  May 20 & 21, 2005.

Freeman MW, Farnier M, Bays HE, Macdonell G, Perevozskaya I, Davies MJ, Mitchel Y, Gumbiner B.  Efficacy and Safety of Coadministered Fenofibrate and Ezetimibe in Patients with Mixed Hyperlipidemia  Abstract/Poster American Heart Association.  November 8, 2004.  New Orleans Louisiana USA.

McKenney J, Davidson M, Saponaro J, Thompson P, Bays H. for the ATGOAL Investigators.  Efficacy and Safety of Atorvastatin Initiated at Optimal Starting Doses in Achieving LDL-C Goals in Patients with Dyslipidemia.  Poster EAS January 15, 2004  Seville Spain 

Bays HE, Deedwania PC, Jones PH, Caplan RJ, Blasetto JW.  Effects of Statins on Low-Density Lipoprotein Cholesterol and High-Density Lipoprotein Cholesterol in Patients 65 Years of Age.  Abstract/Poster American Geriatric Association Meeting.  May 19, 2004  Las Vegas Nevada USA.  Journal of the American Geriatrics Society.  2004 Annual Scientific Meeting Abstract Book Vol 52  No 4  Suppl S1-S246 P 319 April 2004.

Bays HE, Ose L, Fraser N, et. al.  Ezetimibe/Simvastatin is More Effective Than Simvastastin Alone at Reducing Remnant-Like Particle Cholesterol.  Abstract/ Poster American College of Cardiology.  March 3, 2004:1084-179:481A.  New Orleans USA

Ose L, Bays HE, Fraser N, Quinto KL, Reyes R, Sapre A, Tribble T, Donahue SR.  Ezetimibe/Simvastatin Therapy is More Effective than Simvastatin Alone at Reducing Remnant-Like Particle Cholesterol.  Abstract/Poster  European Atherosclerosis Society 74th EAS Congress Seville Spain April 17-20, 2004

Ose L, Bays HE, Fraser N, Quinto KL, Reyes R, Sapre A, Tribble T, Donahue SR. Efficacy and Safety of the Ezetimibe/Simvastatin Combination Tablet Compared with Simvastatin Alone in Patients with Primary Hypercholesterolemia.  Abstract/Poster  European Atherosclerosis Society 74th EAS Congress Seville Spain April 17-20, 2004

Jones PH, Hunninghake DB, Ferdinand KC, Bays HE, Raza A, Caplan RJ, Blasetto JW.  Statin therapies for elevated lipid levels compared across doses to rosuvastatin (STELLAR):  non-high-density lipoprotein cholesterol results and goals.  European Society of Cardiology Congress 2003, Vienna, Austria, August 30 – September 3, 2003.  Eur Heart J  2003;24(Suppl):460 (Abstract P2362).

Bays HE.  New and Upcoming Alternative Lipid Treatment Targets. Oral/Podium Presentation CME Satellite Symposium of "Evolving Role of Combination Therapy in the Management of Dyslipidemia."   International Symposium on Triglycerides, Metabolic Disorders, and Cardiovascular Disease.   July 10th.  2003  New York City USA 
 

Bays HE, McGovern ME, Simmons PD, Kohler RM, Superko RH.  Niacin Extended-Release / Lovastatin Once-Daily combination improves Low-Density and High-Densioty Lipoprotein Subclass Distribution Compared to Starting Doses of Atorvastatin and Simvastatin.  Oral/Podium Presentation July 12th.  2003 International Symposium on Triglycerides, Metabolic Disorders, and Cardiovascular Disease.  New York City USA


Bays HE, McGovern ME, Simmons PD, Wu TY.  Time Course to Achieve Non-High-Density Lipoprotein Cholesterol Goals with Niacin Extended-Release / Lovastatin as Initial Therapy Versus Atorvastatin and Simvastatin.  Abstract / Poster, July 11th. 2003 International Symposium on Triglycerides, Metabolic Disorders, and Cardiovascular Disease.  New York City USA

Jones, PH for the STELLAR Study Group.  Statin Therapies for Elevated Lipid Levels Compared Across Dose Ranges to Rosuvastatin:  Low-Density Lipoprotein-Cholesterol and High-Density Lipoprotein-Cholesterol Results.   Amer Coll Card  876-2 Chicago 2003

Bays HE, Weiss S, Gagne C, et. al. Ezetimibe added to ongoing statin therapy for treatment of primary hypercholesterolemia. Oral/Podium Presentation. 2002 Amer Coll Card Vol 39 no. 5 (suppl A) 833-4 p. 245A

Bays HE., McGovern ME, Simmons PD. Lipoprotein effects of a new dual component drug (extended-release niacin / lovastatin) compared to starting doses of atorvastatin and simvastatin. Oral/Podium Presentation. 2002 Amer Coll Card Vol 39 no. 5 (suppl A) 833-4 p. 245A

MacDougall D, Nyberg J, Bays H, Dujovne C. Efficacy and Tolerability of a novel lipid-altering agent, CI-1027 (gemcabene), in patients with low high density lipoprotein cholesterol and normal or elevated triglycerides. Abstract presentation at Cardiovascular Pharmacotherapy Congress. Montreal May 2002.

Bays HE, Hunninghake D, Chitra R, Carbarns I. More patients achieve national cholesterol education program adult treatment panel III low density lipoprotein cholesterol goals with rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. April 23-26, 2002. Poster American Heart Association Pacific Scientific Forum. 42nd Annual Conference on Cardiovascular Disease Epidemiology and Prevention. Honolulu Hawaii.

Barter P, Shepherd J, Brown WV, Bays H, Southworth H, Strutt K. Rosuvastatin significantly improves lipid parameters and ability to achieve low-density lipoprotein cholesterol goals compared with pravastatin. J Am Coll Cardiol 2002;39 (Suppl B):142B:2799.

Bays HE, Weiss S, Mata P, Gagne C, Gumbiner G, Melino M, Quinto K, Cho M.  Ezetimibe added to on-going statin therapy for treatment of primary hypercholesterolemia.  June 12-15th, 2002. Poster 6th International Symposium on Global Risk of Coronary Heart Disease and Stroke.  Florence Italy

Bays-Harold; Mitchel-Yale; Mercuri-Michele. Effect of simvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I in patients with elevated triglyceride blood levels. Presented at the 61st Scientific Sessions of the American Diabetes Association, Philadelphia, Pennsylvania, USA, June 22-26, 2001. Diabetes 2001;50(Suppl 2):A141.

Knopp RH, Bays H, Manion CV, Lipka LJ, Melani L, LeBeaut AP, Suresh R, Veltri EP, for the Ezetimibe Study Group. Effect of ezetimibe on serum concentrations of lipid-soluble vitamins [abstract]. Atherosclerosis. 2001;2(suppl):90. Abstract P175.

Knopp RH, Bays HE, Mardon CV, Lipka LJ, Melani L. Effect of ezetimibe on serum concentrations of lipid-soluble vitamins. Abstract P175. 72nd Congress of the European Atherosclerosis Society. Glasgow, 20-23. May, 2001.

Bays HE, Knopp RH, Mardon CV, Lipka LJ, LeBeaut AP, Suresh-R, Veltri-E-P.  Ezetimibe does not decrease the response to cosyntropin stimulation.  Atherosclerosis-Supplements  (2,  No. 2, 95, 2001)

Bays HE, Knopp RH, Mardon CV, Lipka LJ, LeBeaut AP. Ezetimibe does not decrease the response to cosyntropin stimulation. Conference Abstract P193. 72nd Congress of the European Atherosclerosis Society. Glasgow, 20-23. May, 2001.

Brown WV, Zedler BK, Bays HE, Hassman HA, Chitra RR. Long-term efficacy and safety of rosuvastatin: results of a 52-week comparator-controlled trial versus pravastatin and simvastatin. Eur. Heart J. 2001 Sep; 22(Suppl.): 270 Abstract 1526.

Stein EA, Rhyne JM, McKenney J, Bays H, Roth E, Breed S, Rolleri R. Intestinal bile acid transport (IBAT) inhibition: results of a 4 week pilot study of 264w94, a novel IBAT inhibitor in hypercholesterolemia. Abstract. XIV International Symposium on Drugs Affecting Lipid Metabolism New York, New York (USA) September 9-12, 2001

Lipka-L-J, LeBeaut-A-P, Veltri-E-P, Mellars-L-E, Bays-H-E, Moore-P-B. Reduction  of  LDL-cholesterol  and  elevation  of HDL-cholesterol in    subjects  with  primary  hypercholesterolemia  by  SCH  58235: pooled analysis of two phase II studies. J-Am-Coll-Cardiol  (35,  No.  2,  Suppl. A, 257A, 2000)

Bays H, Drehobi M, Rosenblatt S. et. al. Low density lipoprotein cholesterol reduction by SCH 58235 (ezetimibe), a novel inhibitor of cholesterol absorption in 243 hypercholesterolemic subjects: results of a dose-response study. Atherosclerosis. 2000;151:133 Abstract

Bays H, Drehobl M, Rosenblatt S, Toth P, Dujovne C, Knopp R, Lipka L,  Cuffie-Jackson C.  Low density lipoprotein cholesterol reduction by SCH 58235 (ezetimibe), a novel inhibitor of cholesterol absorption in 243 hypercholesterolemic subjects: results of a dose-response study. Atherosclerosis. 2000;151:133, also abstract/poster XIIth   International   Symposium   on   Atherosclerosis,  Stockholm, Sweden, 2000.

Isaacsohn J, Hunninghake D, Schrott H, Dujovne C, Knopp R, Weiss S, Bays H, Crouse J, Davidson M, Samuel P, Keilson L, McKinney J, Korenman S, Dobs A, Krauss R, Stein E, Cho M, Plotkin D, Mitchel Y. The Efficacy of Simvastatin in Patients with Hypertriglyceridemia. 71st EAS Congress Athens Greece May 26-29, 1999.

Stein E, Plotkin D, Stepanavage M, Huninghake D, Bays H, Davidson M, Dujovne C, Keilson L, Korenman S, Robertson D, Weiss S, Mercuri M. Simvastatin is and Effective Lipid Altering Treatment in Type IV Hyperlipidemia. 71st EAS Congress Athens Greece May 26-29, 1999.

Krauss-Ronald-M; Isaacsohn-Jonathan; Hunninghake-Donald; Schrott-Helmut; Dujovne-Carlos-A; Knopp-Robert-H; Weiss-Stuart-R; Bays-Harold; Stein-Evan-A; Cho-Meehyung; Plotkin-Diane-J; Mitchel-Yale-B. Changes in atherogenic lipoprotein fractions with simvastatin in patients with hypertriglyceridemia. Presented at the 72nd Scientific Sessions of the American Heart Association, Atlanta, Georgia, USA, November 7-10, 1999.  Circulation 1999;110(18 Suppl):I.

Hunninghake-D-B; Plotkin-D; Stepanavage-M; Bays-H; Davidson-M-H; Dujovne-C-A; Keilson-L-M; Korenman-S-G; Robertson-D-G; Stein-E-A; Weiss-S-R; Mercuri-M. Large, dose dependent effects of simvastatin 40 and 80 mg/day in combined hyperlipidemia. Presented at the 48th Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana, USA, March 7-10, 1999. Journal of the American College of Cardiology 1999;33(2 Suppl A):244A.

Davidson, M. H., Plotkin, D., Hunninghake, D., Stein, E. A., Bays, H., Dujovne, C. A., Keilson, L. M., Korenman, S. G., Weiss, S. R., Robertson, D. G., Stepanavage, M. and Mercuri, M. (1998). Efficacy of simvastatin 40 and 80-mg/day in combined hyperlipidemia. Thirteenth International Symposium on Drugs Affecting Lipid Metabolism (DALM), Florence, May 30-June 2, Abstracts, p. 78.

BOOKS

Bays HE. Chapter 22. Cholesterol Absorption Inhibitors (Ezetimibe) and Bile Acid Binding Resins (Colesevelam HCl) as Therapy for Dyslipidemia in Patients with Diabetes Mellitus. Contemporary Diabetes. Humana Press. Springer New York Heidelberg Dordrecht London ISBN 978-1-4614-7553-8 Copyright 2014; 415-433.

Bays HE. Chapter 21: Fish Oils in the Treatment of Dyslipidemia and Cardiovascular Disease. The John Hopkins Textbook of Dyslipidemia, by Peter O Kwiterovich, Jr. Johns Holpkins Medicine ISBN 13:978-0-7817-8265-4 ISBN 10: 0-7817-8265-1 Wolters Kluwer Health; Lippincott Williams & Wilkins. Copyright 2010; 245-257.

Bays H. Chapter 44: Investigational Agents Affecting Atherogenic Lipoproteins. Clinical Lipidology: A Companion to Braunwald's Heart Disease, by Christie Ballantyne MD. ISBN-13: 978-1-4160-5469-6 ISBN-10: 1-4160-5469-3 Saunders. Dec 2008; 530-543.

Cromwell WC, Bays HE, Toth PP.  Lipoprotein subfraction analysis using nuclear magnetic resonance spectroscopy.  Markers in Cardiology:  A Case-Oriented Approach.  Part 3, Chapter 19, pages 217 - 250.  2007 Blackwell Publishing 

Bays HE. "Diet and Exercise" in Dujovne CA, Held J, Peterson GC, Harris WS, et.al. "A Change of Heart" 1993:Westport Publ.

 

L-MARC HOME PAGE